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Abstract 
xmi-er 1, Xenopus mesoderm induction early response 1 gene, was initially 
discovered as a developmentally regulated gene that was transcribed in response to 
fibroblast growth factor (FGF). FGF family members are involved in mitogenesis, 
differentiation, and angiogenesis (Baird and Klagsbrun, 1991). Additional studies 
revealed that XMI-ER1 functioned as a potent transcriptional activator, where theN-
terminal acidic domain was responsible for the activity. The human orthologue of mi-er 1, 
hmi-er 1, was also isolated and was shown to be 91% similar to xmi-er 1. Further analysis 
revealed that hmi-er 1 expression levels were upregulated in breast carcinoma cell lines 
and tissue, and that it acted as a transcriptional repressor by interaction with a histone 
deacetylase, HDAC1, through its ELM2 domain (Paterno et al., 1998; Paterno et al., 
2002; Ding et al., 2003). HDACs and histone acetyltransferases (HATs) are enzymes 
that play a very important role in modifying histones, altering chromatin, and regulating 
transcription. 
In this study, we further investigated the role ofhMI-ER1 in the regulation of 
transcription. We demonstrated that hMI-ER1B, an isoform ofhMI-ER1, inhibited the 
HAT activity of the coactivator Creb-binding protein (CBP). hMI-ER1B physically 
interacted with CBP, and the interaction led to the inhibition ofCBP HAT activity. The 
interaction required a region within aa 1-179 ofhMI-ER1, an area containing several 
acidic regions. Within the CBP molecule, a region located between aa 1092-2441, which 
contains a bromodomain, a C/H2 and C/H3 domain, a HAT domain, and a Q rich 
1 
domain, was required for the interaction. The results indicate that hMI-ERl interacts 
with CBP and that it has the potential to play a role in HAT -mediated transcription. 
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Chapter 1: Introduction 
1.1 DNA and Chromosomes 
Deoxyribonucleic acid (DNA) are molecules that carry the genetic information 
necessary for the organization and function of most living cells and conveys this 
information from generation to generation. Genes are regions ofDNA that are 
responsible for a discrete hereditary characteristic, which usually corresponds to a single 
RNA or protein. 
In eukaryotes, the DNA and genes are packaged into a set of chromosomes 
(Figure 1.1 ). The proteins that bind to DNA to form the chromosomes are known as 
histones and nonhistone chromosomal proteins. The complex of both proteins with the 
DNA is known as chromatin. Because the uncoiled length of the total human genome 
would be approximately 40 inches long, the structure of the chromatin helps to condense 
the DNA within a cell. Histones are responsible for the most basic level of chromosome 
organization, and are responsible for forming the nucleosome. Histones have a high 
proportion of positively charged amino acids (lysine and arginine), and they therefore 
bind tightly to the negatively charged DNA. Unfolded chromatin has the appearance of 
"beads on a string", with the "string" being the DNA and each "bead" consisting of DNA 
wound around a protein core formed from histones (Figure 1.1 ). Each individual 
nucleosome core is made up of a complex of eight histone proteins-two molecules each 
ofhistones H2A, H2B, H3 and H4. A fifth histone, H1, may be attached to the outside of 
the bead. In addition to its histone fold, each of the core histones has a long histone 
1 
Figure 1.1 
short region of /"L'\./'L"'\. /"'.r\. rY:\. /'1'\:' 
DNA double helix 'X/ \J(.J'VJ '-X/ "'\YJ '\. 
''beads-on-a-string'' 
form of chromatin 
30-nm chromatin 
fiber of 
packed nucleosomes 
section of 
chromosome in an 
extended form 
chromosome 
Levels of chromatin packaging 
The above diagram is a schematic illustrating the many levels of chromatin postulated to 
give rise to the highly condensed chromosome. Adapted from Bruce eta/. (1989). 
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N-terminal amino acid tail, which extends out from the histone core. These histone tails 
often undergo covalent modifications, which in the end, control the chromatin structure. 
The "beaded string" further undergoes higher-order packaging. For instance, with 
the help of histone Hl the "beaded string" can coil to form a chromatin fiber which 
consists of a tightly wound coil with 6 nucleosomes per tum. The chromatin fiber further 
forms loops called looped domains, and in a mitotic chromosome the looped domains 
fold themselves to further compact the chromosome (Alberts et al., 2002). 
1.2 Protein Synthesis: Transcription and Translation 
DNA does not directly make a protein within a cell. Ribonucleic acid (RNA) is 
the bridge between the genetic material and protein synthesis. When a particular protein 
is needed within a cell, RNA is synthesized through a process known as transcription. 
The RNA molecules that are copied from these genes are called messenger RNA 
(mRNA) molecules. Like DNA, RNA is made up of four different types of nucleotide 
subunits. Overall, there are three eukaryotic RNA polymerases, RNA polymerase I, II, 
and III. The enzymes called RNA polymerase II transcribe the genes whose RNAs will 
be translated into protein. In general, these enzymes are responsible for opening and 
uitWinding a small portion of the DNA double helix to expose the bases on each DNA 
strand. The enzyme is then responsible for linking together the RNA nucleotides 
complementary to the nucleotide of DNA. Overall, the three key steps in transcription are 
polymerase binding and initiation, elongation and termination. 
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RNA polymerases bind to regions of DNA known as promoters. A promoter 
includes the initiation site, where transcription actually begins, and a large number of 
nucleotides upstream from the initiation site. RNA polymerases cannot, however, 
recognize and bind to a promoter by itself. Transcription factors (TF) are proteins that 
help to position the enzyme correctly on the promoter, help in the unwinding of DNA, 
and help to release the RNA polymerase from the promoter once transcription has begun. 
These sequence specific DNA binding proteins must therefore be bound to DNA to form 
a functional promoter. 
As mentioned earlier, DNA is packaged into nucleosomes with further higher 
order packaging. Therefore, transcription initiation requires transcription activators, 
mediators and chromatin-modifying proteins. Transcriptional activators bind to specific 
sequences in DNA and help to recruit RNA polymerase II, and mediators play a role in 
allowing easy communication between activators and transcription factors. Furthermore, 
transcription initiation in a cell often requires the presence of chromatin remodeling 
enzymes which include chromatin remodeling complexes and histone acetylases. 
Chromatin remodeling complexes play a very important role in remodeling the 
nucleosome structure. For instance, some proteins within the complex can change the 
stPUcture of the nucleosomes temporarily so that the DNA becomes less tightly bound to 
the core histones, permitting the easy access to nucleosomal DNA by other proteins. 
Often, these proteins are involved in gene expression, DNA replication, and repair. In 
addition, chromosomal remodeling complexes may also function to re-form nucleosomes 
when access to DNA is no longer required. 
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Following the binding of RNA polymerases and initiation of transcription, RNA 
polymerase II moves along the DNA and the RNA strand is further elongated. As soon as 
RNA polymerase II has produced approximately 25 nucleotides of RNA, the 5' end of 
the new RNA molecule is modified by the addition of a special nucleotide, known as 
"capping". The "cap" helps the cell to distinguish mRNAs from other types of RNA 
molecules found within the cell. The RNA molecule also undergoes a process of RNA 
splicing, which involves the removal of non coding intron sequences. The 3' end is 
modified by addition of a series of adenylic acid nucleotides immediately after its 
cleavage. Following the production of the mRNA molecule is the process of translation. 
Translation is the process of protein synthesis, which occurs under the direction of the 
mRNA molecule. A protein is built from a series of codons along an mRNA molecule, 
where a single codon is made up of any three nucleotides. Transfer RNA (tRNA) 
functions to transfer amino acids from the cytoplasm to a ribosome. The ribosome, in 
tum, adds each amino acid brought to it to the growing end of the protein. While a 
protein is being made it coils and folds to form a functional protein with a very specific 
conformation. Additional steps, such as chemically modification, may be required but the 
overall process,ef protein synthesis from DNA is complete (Alberts et al., 2002). 
1.3 Histone Acetyltransferases (HATs), Deacetylases and Regulation 
Histone acetylation occurs when an acetyl group from acetyl-coenzyme A (acetyl-
CoA) is added to the ~::-amino group at specific lysine residues within a histone's basic N-
terminal tail region. Lysine acetylation, which neutralizes part of a tail region's positive 
5 
charge, can weaken the interaction between histones and the negatively charged DNA. 
The weakened interaction destabilizes the nucleosomes giving transcriptional regulators 
increased access to the DNA (as reviewed in Sterner and Berger, 2000a). 
Histone acetyltransferases (HATs) are the enzymes that function to acetylate the 
histones. Through their interaction with specific transcription factors they are targeted to 
specific promoters, where they locally modify histones and regulate transcription (as 
reviewed in Legube and Trouche, 2003b). Table 1.1 shows a partial list of known and 
putative HATs. Yeast GenS is the best characterized of all the HATs, both structurally 
and functionally. Studies have shown that GenS HAT activity directly correlates with cell 
growth, in vivo transcription, and histone acetylation at the GenS-dependent promoters 
(as reviewed in Kuo eta!., 1998). In vitro, GenS was shown to acetylate histone H3 
strongly and H4 weakly (Ornaghi eta!., 1999). GenS and p300/CREB-binding protein-
associated factor (PCAF) are two closely related HATs found in mammals (as reviewed 
in Sterner and Berger, 2000b). The function of human GenS is very similar to its role in 
yeast, in that it was found to carry out transcription regulatory roles (Candau et al., 1996). 
PCAF studies revealed that it shares the same functional roles as GenS and that it 
interacts with two other HATs, p300 and Creb Binding Protein (CBP). Studies have 
shown that PCAF can act as a transcriptional coactivator in a HAT -dependent manner 
and stimulate transcription when bound either to a promoter-proximal site or at a distant 
enhancer (Krumm et al., 1998), where distant enhancers are enhancers that can be located 
a significant distance from promoters. 
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It is important to note that histone acetylation is a reversible process, whereby 
histone deacetylases (HDACs) are able to remove the acetyl groups from lysine residues. 
The deacetylation ofhistones would stabilize the nucleosomes leading to a possible 
decrease in gene transcription. Both histone acetylation and deacetylation are two 
regulatory processes that work together to achieve appropriate levels of 
transcription (Figure 1.2; Braunstein eta!., 1996). 
HATs and HDACs both play a major role in the control of cell fate and 
misregulation of these proteins is involved in the development of some human tumors. 
Abnormal acetylation or deacetylation leads to such diverse disorders as leukemia, 
epithelial cancers, fragile X syndrome and Rubinstein-Taybi syndrome (as reviewed in 
Timmermann et al., 2001). Because HAT and HDAC activities are so important, their 
activity is known to be tightly regulated within a cell. One such mechanism of regulation 
is to regulate their expression levels. Although not much is known about such regulation, 
it has recently been shown that Hdacl mRNA expression is induced by histone 
hyperacetylation, suggesting that feedback loops exist (Hauser et a!., 2002). Another 
main mechanism of regulation is through the regulation of the enzymatic activity itself. 
For instance, the activity of many HATs and HDACs has been shown to be regulated 
thJiough phosphorylation, whereby phosphorylation can actually stimulate HAT activity. 
In addition, protein-protein interactions also play a role in regulating HAT activity. 
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Table 1.1: Summary of known and putative HATs (adapted from Sterner et al., 
1999). 
HAT Orthologues found in: 
GenS Yeast to Humans 
Hatl Yeast to Humans 
PCAF Humans, mice 
Elp3 Yeast 
Hpa2 Yeast 
Sas2 Yeast 
Tip60 Humans 
MOZ Humans 
MORF Humans 
MOF Drosophila 
HBOl Humans 
CBP Various multicellular organisms 
p300 Various multicellular organisms 
"' 
SRC-1 Humans, mice 
ACTR Humans, mice 
TIF2 Humans, mice 
TFIIIC Humans 
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There are many proteins known to interact with HATs, and through their 
interaction they can stimulate histone acetylation activity (as reviewed in Legube and 
Trouche, 2003b). For example, transcription factors such as HNF1-a, Sp1, and Zta can 
stimulate the activity of CBP and p300, two well known histone acetyltransferases (Chen 
et al., 2001; Soutoglou et al., 2001; Li et al., 2003). In comparison, the transcription 
factors Msx3, Hox proteins and Twist can interact with HATs and block HAT activity 
(Hamamori et al., 1999; Mehra-Chaudhary et al., 2001; Shen et al., 2001). Lastly, histone 
acetylase and deacetylase activity can be regulated by the availability of co factors such 
as acetyl-coenzyme A (as reviewed in Legube and Trouche, 2003a). 
1.4 Creb Binding Protein (CBP) - A Histone Acetyltransferase 
CREB Binding Protein (CBP) was originally identified in 1993 through its ability 
to co-immunoprecipitate with the phosphorylated form of cAMP-response-element-
binding protein (CREB) (Chrivia et al., 1993). CREB is a 43 kDA transcription factor 
that binds to cAMP-response element (CRE) via a leucine zipper motif present at its C 
terminus. Upon phosphorylation on Ser133, active CREB affects transcription ofCRE-
dependent genes by interacting with the CREB-binding Protein, CBP. CBP plays a very 
important role in bridging the CRE/CREB complex to components of the basal 
transcriptional apparatus and also acts as a transcriptional coactivator. CREB-mediated 
transcription regulates cellular responses such as neuronal signaling, cell proliferation 
and apoptosis (as reviewed in Andrisani, 1999). 
9 
Nucleosomes 
Figure 1.2 A general model of histone acetyltransferase and histone deacetylase 
action. Through a physical interaction between sequence-specific transcription factor 
(TF), histone acetyltransferases (HATs) and deacetylases (HDACs) are recruited to their 
targeted promoters. Both HATs and HDACs can be found within a complex of other 
histone acetyltransferases or deacetylases, "enzymatic complex", and function to modify 
chromatin structure. Previous studies also indicate that HATs and HDACs can modify 
proteins other than histones, as designated by "Protein X" (Adapted from Legube and 
Trouche, 2003b ). 
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In 1996, CBP was first described to have intrinsic HAT activity (as reviewed in 
Ogryzko eta!., 1996; Bannister and Kouzarides, 1996a). At that time, only PCAF and 
yeast GenS had been identified as having HAT activity. Unlike other HATs, CBP is able 
to acetylate all four core histones in vivo, whereas GenS and PCAF only acetylate 
histones H3 and H4 (as reviewed in Sterner and Berger, 2000b). Shortly after, the HAT 
domain was mapped between residues 1099-1758 and it was therefore this region that 
acetylated all core histones in vitro (Bannister and Kouzarides, 1996b ). The overall 
observations suggested for the first time that CBP was not just an adaptor between DNA-
binding factors, transcription-initiation factors, or other described HATs, but that CBP 
plays a role in transcriptional regulation by histone acetylation and chromatin 
remodeling. CBP, through its HAT activity, stimulates transcription of specific genes by 
interacting with numerous promoter-binding transcription factors such as CREB, nuclear 
hormone receptors, and oncoprotein-related activators such as c-Fos, c-Jun and c-Myb 
(Bannister and Kouzarides, 1996c; Sterner and Berger, 2000a). 
1.4.1 CBP Gene and Functional Domains 
The human CBP locus is located on chromosomal region 16p13.3 and extends 
apt'.lroximately 190 Kb (Wydner et al., 1995). When translated, the CBP gene yields a 
protein of2440 and 2441 amino acid residues in humans and mice, respectively (Chrivia 
et al., 1993). The CBP protein is evolutionary conserved, sharing 95% identity between 
human and mouse. Orthologues have also been identified in a number of other 
organisms, including Drosophila melanogaster (fruit fly), Caenorhabditis elegans 
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(nematode worm), and Arabidopsis thaliana (self-pollinating weed) (as reviewed in 
McManus and Hendzel, 2001). The high degree of similarity suggests that CBP plays a 
very critical role in cellular functions. 
The CBP protein resolves to a band of approximately 265kDa on a sodium 
dodecyl sulphate (SDS) polyacrylamide gel and comprises several different conserved 
domains. TheN terminus is made up of a nuclear receptor binding domain (RID), kinase 
induced interacting domain (KIX), three cysteine-histidine-rich domains (CHI, CH2, 
CH3), a bromodomain, two zinc finger motifs, the histone acetyltransferase domain 
(HAT) and a glutamine Rich (Q Rich) domain (Figure 1.3). The RID, CH1, CH2, CH3 
and the KlX domains are thought to be important in mediating protein-protein 
interactions, since a number of cellular and viral proteins bind to these regions. The 
bromodomain is an evolutionary conserved domain and found in nearly all histone 
acetyltransferases. It has been recently discovered to function as an acetyl-lysine binding 
domain (Dhalluin et al., 1999; Hudson et al., 2000; Jacobson et al., 2000). Overall, it has 
been shown that CBP associates with at least 45 different molecules including 
transcription factors, signaling molecules, and nuclear hormone receptors (as reviewed in 
Giles et al., 1998). As mentioned, CBP also has a HAT domain, found in the central 
r~ion of the protein. It is this domain that gives CBP its intrinsic histone 
acetyltransferase activity, labeling CBP as a histone acetyltransferase. 
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Figure 1.3 Structure of CBP, its functional domains and interacting regions 
Schematic representation of mouse CBP, illustrating the amino acid residues 1-2441. 
Listed are the previously identified domains as a reference. The domains listed include 
the receptor interacting domain (RID), three cysteine or histidine rich domains (C/H-1,-
2, -3), a kinase-induced interacting domain (KIX), a bromodomain (Br), a histone 
acetyltransferase domain (HAT), and a glutamine -rich domain (Q Rich). The bars, 
located below the diagram, indicate the interacting regions of CBP with the partial list of 
CBP-interacting proteins given below. Adapted from Vo and Goodman, 2001. 
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1.4.2 CBP and Transcriptional Regulation 
In addition to the role of CBP as a histone acetyl transferase, CBP may also play a 
role in transcriptional regulation by acting as a scaffold for the assembly of multiprotein 
complexes (as reviewed in Chan and LaThangue, 2001). For instance, CBP is often 
found in association with three additional HATs; PCAF (as reviewed in Ogryzko et al., 
1996), SRC-1 (steroid receptor coactivator-1; Yao eta!., 1996; Spencer et al., 1997), and 
ACTR (activator ofretinoic acid receptor; Chen et al., 1997). By providing a scaffold for 
the assembly of transcription cofactors, CBP may act to increase the concentration of 
these factors in the transcriptional environment (as reviewed in McManus and Hendzel, 
2001). 
It is also important to note the role of CBP in the acetylation of nonhistone 
proteins and gene expression. Enzymes that acetylate non-histone proteins are referred to 
as factor acetyltransferases (FATs). FATs seem to either promote or reduce protein-
protein interactions that affect transcriptional activation of specific genes. CBP was first 
identified as a FAT when it was shown to acetylate the protein p53 (Gu and Roeder, 
1997). p53 is a tumor suppressor with most of the critical functions believed to occur 
through its ability to activate genes involved in the response to DNA damage, such as 
IIltirine double minute (mdm-2), p21, cyclinG, and bax. Inactivation ofp53 function 
appears to be critical to tumorigenesis in all different types of human cancers (Vogelstein 
et al., 2000). Studies have demonstrated that p53 interacts with CBP and that the 
interaction contributes to the transcriptional activation of the p53-responsive mdm-2, p21, 
and bax promoters (Avantaggiati eta!., 1997; Lill eta/., 1997; Gu and Roeder, 1997). 
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Further analyses ofp53 and CBP have shown that the acetylation ofp53 by CBP 
dramatically increases its DNA binding ability (Gu and Roeder, 1997). CBP has also 
been shown to acetylate several additional transcriptional regulators, including the 
activators GATA-1, and erythroid kruppel-like factor (EKLF) (as reviewed in Imhof et 
a!., 1997; Boyes eta!., 1998). Exactly how acetylation affects the transcriptional 
properties of these proteins in not yet completely understood (as reviewed in Goodman 
and Smolik, 2000). 
1.4.3 CBP and disease 
The gene encoding CBP, located on 16p13.3, was reported as the causative gene 
ofRubinstein-Taybi syndrome (RTS) (Petrij eta!., 1995a; Petrij eta!., 2000b). RTS is an 
autosomal-dominant disease that is present at or before birth, and is characterized by 
facial abnormalities, broad thumbs and toes, short stature and mental 
retardation. The first English description ofRTS occurred in 1963 (Rubinstein and Taybi, 
1963), and included additional characteristic features such as growth retardation, 
microcephaly (small brain at birth), and keloid formation (formation of a sharply 
elevated, irregular-shaped, enlarging scar). 1 out of 300 patients institutionalized for 
mental retardation is diagnosed with RTS, suggesting that the disease is fairly common 
(as reviewed in Goodman and Smolik, 2000). The underlying cause ofRTS was shown to 
be microdeletions and chromosomal breakpoints within the CBP locus. Most RTS 
individuals are heterozygous for the mutations in CBP, suggesting that a full complement 
of the CBP gene is critical for normal development (Petrij eta!., 1995b). Recent evidence 
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suggests that it may be the loss of the HAT activity ofCBP that may cause RTS. 
Sequence analysis revealed that 100% of the individuals with mutations of CBP have 
either a protein truncating mutation that lacks all or part of the HAT domain or a 
missense mutation from arginine to proline. Further in vitro studies have shown that the 
truncated CBPs analyzed from patients in the study, as well as the missense mutation 
CBP, labeled CBP R1379P, do not have HAT activity. Because HAT activity ofCBP is 
required for transcriptional activity ofCREB (Korzus et al., 1998;Kurokawa et al., 1998), 
additional in vitro assays were performed. Using microinjection experiments the 
transcriptional potency of CBP R1379P was measured. The results show that CBP R1379P 
was unable to transactivate CREB (Murata et al., 2001). 
Patients with RTS have also been shown to have an increased predisposition for 
cancer (as reviewed in Miller and Rubinstein, 1995).The precise incidence of tumors in 
RTS is not known, but estimates have been in the range of 5% (as reviewed in Goodman 
and Smolik, 2000). Unfortunately, the recognition that RTS is due to mutations in CBP 
has not been very useful clinically, as only 3-25% of patients have deletions large enough 
to be detected by fluorescence in situ hybridization (FISH) or the protein truncation test 
(Taine et al., 1998; Petrij et al., 2000a). 
"' As direct evidence that the loss of one copy of the mammalian CBP gene affects 
pattern formation, CBP heterozygous and CBP-deficient mutant mice were generated by 
gene targeting. Consistent with RTS patients, mice lacking one functional copy of the 
CBP allele exhibited some of the skeletal abnormalities as seen with RTS patients. CBP 
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was further found to be essential for mouse embryonic development in that mice lacking 
two functional CBP alleles die 8-10 days post conception (Tanaka et al., 1997). 
1.4.4 CBP and Cancer 
Since chromatin remodeling enzymes, such as CBP, play an essential role in 
transcription regulation, it is not surprising that they have been linked to cancer. The 
involvement of the CBP gene has been implicated in a number of hematological 
malignancies, including acute myeloid leukemia (AML), chronic myeloid leukemia 
(CML) and myeloidysplastic syndrome (MDS) (McManus and Hendzel, 2001). AML, 
CML, and MDS affect the white blood cells which increase in the bone marrow, replace 
the normal blood cells, and spread throughout the body. It was initially discovered that 
the CBP gene was involved in leukemia-associated chromosomal translocations. 
Translocations are chromosomal abnormalities that occur when chromosomes break and 
the fragments rejoin to other chromosomes. The process brings two previously unlinked 
segments of the genome together. The translocations found in hematological 
malignancies involving CBP generally result in fusion products that preserve most of the 
CBP molecule, suggesting that the disease mechanism does not necessarily involve the 
1~ of function of the histone acetyl transferase activity as seen in RTS patients (Blobel et 
al., 1998). It is possible that CBP has an altered function through fusion to another 
molecule. For example, AML-leukemic blast cells (immature white blood cells) 
containing a CBP translocation, have the CBP gene fused to the Monocytic Leukemia 
Zinc Finger (MOZ) gene. The fusion results in a small deletion of the N-terminal266 
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amino acids of CBP leaving the rest of the molecule intact (Borrow et al., 1996; Korzus 
et al., 1998; Kurokawa et al., 1998). 
A study conducted by Kung et al., 2000 further strengthens the role of 
dysfunctional CBP protein in hematological malignancies. Mice engineered to contain a 
null mutation in one CBP allele developed a variety of hematological abnormalities, 
including extramedullary myelopoiesis (formation of tissue resembling bone marrow, 
outside of the bone marrow), splenomegaly (enlargement of the spleen), and lymph node 
hyperplasia (increased number of cells in lymph nodes). With advancing age, the mice 
developed a very high incidence of hematological malignancies, such as lymphocytic 
leukemia. Overall, nearly 40% of the CBP heterozygotes either developed tumors or 
harbored tumorigenic cells (Kung et al., 2000). 
1.5 MI-ERl 
Mesoderm Induction garly Response l gene, or mi_erl, was initially discovered 
as a developmentally regulated gene whose expression levels were increased during 
mesoderm induction by fibroblast growth factors (FGF) in Xenopus laevis (Paterno et al., 
1997). In vertebrates, FGFs belong to a 22 member family known to bind to heparin and 
heparan sulphate, and share a highly conserved 140 amino acid central core (as reviewed 
in Ornitz and Itoh, 2001). It has been shown that many members of the FGF family are 
involved in mitogenesis, differentiation, and angiogenesis (Baird and Klagsbrun, 1991). 
It has also been previously shown that deregulated FGF signaling pathways are involved 
in tumor development and progression (as reviewed in Powers et al., 2000). FGF activity 
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has also been implicated in mesoderm induction and formation in Xenopus embryonic 
tissue (Slack et al., 1987). During mesoderm induction, FGF binds to FGF receptors that, 
upon tyrosine phosphorylation, form a signaling complex by recruiting signaling 
molecules (Gillespie et al., 1992). The binding of the intracellular substrates then leads to 
the activation of various signal transduction pathways. In a signal transduction pathway, 
the end result is the transcription of target genes. The first genes to be transcribed are 
referred to as the immediate-early or early-response genes. Many of the known early 
response genes are known as transcription factors, in that they play an important role in 
initiating or repressing the transcription of other genes. 
In efforts to further explain the molecular mechanisms ofFGF signal 
transduction, a PCR-based differential display method was used to identify and 
characterize genes that are expressed early during the cellular response to FGF. The 
results revealed a novel Xenopus gene, known as Xmi-er 1, which demonstrated an 
increase in steady state levels upon stimulation with FGF. The PCR product was then 
used to obtain a 2.3 kilobase pair eDNA, with the open reading frame predicted to encode 
a protein of 493 amino acids. In order to further investigate the possibility that Xmi-er 1 is 
an immediate-early gene, the FGF-induced increase was measured in the presence and 
absence of cycloheximide. Cycloheximide, which is a protein synthesis inhibitor, did not 
prevent the increase in XMI-ER1 expression levels. Taken together the results suggest 
that the transcription of the gene is very rapid and is not dependent on de novo protein 
synthesis, furthering supporting the idea that Xmi-er 1 is an immediate early gene. 
Additional analysis also revealed that the Xmi-er 1 sequence contained two putative 
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nuclear localization signals, as well as stretches of acidic residues. Immuno-
histochemistry and transient transfections in HEK 3T3 cells revealed that the XMI-ER1 
protein is targeted to the nucleus and theN-terminus functions as a potent transactivator 
(Paterno et al., 1997). 
Subsequent studies on this gene led to the discovery of a human orthologue of mi-
er1 (Paterno et al., 1998). Amino acid comparisons ofboth the Xenopus and human mi-
er1 (hmi-er1) isoforms showed a 91% sequence similarity overall, with 100% similarity 
in the common internal domains. 
Because FGFs play a role in the pathology of human cancers, the expression 
levels ofhMI-ER1 in various tissues and cell lines were investigated. Reverse 
transcription-polymerase chain reaction (RT-PCR) revealed that hmi-er1 expression was 
upregulated in breast carcinoma cell lines and breast tumors, while remaining 
undetectable in normal breast cell lines and breast tissue. The results suggest that hMI-
ER1 plays a role in the neoplastic state ofhuman breast carcinoma (Paterno et al., 1998). 
With the evidence that hmi-er1 associates with the neoplastic state ofhuman 
breast carcinoma and the potential role of mi-er 1 as a transcription activator in the 
regulation of embryonic development, it was of importance to examine the human mi-er 1 
gMe further. Human mi-er 1 cDNAs were initially isolated, cloned and characterized 
using polymerase chain reaction techniques. It was initially shown that the hmi-er 1 gene 
was a single copy gene located at position 1 p31.2, spans 63 Kb and consists of 17 exons 
in total (Figure 1.4). Sequence analysis of the variant forms of hmi-er1 cDNAs further 
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Figure 1.4 Structure of the human mi-er 1 gene and splice variants. The 17 exons 
ar! shown in black, the introns as horizontal lines, the gray area represents the facultative 
intron, and the white area represents the position of a and 13 carboxy-terminal coding 
regions. (A) The exonlintron organization ofthe hmi-er1 gene is shown, where the exons 
are numbered below the schematic. (B) Schematic illustrating three distinct 5' ends, 
referred to as N1, N2, N3. Also shown is the variation in the 3' end generated from 
alternative splicing, alternate promoter usage and/ or PAS. Reproduced from Paterno et 
al., 2002. 
21 
revealed 3 possible 5' ends, referred to as Nl, N2 and N3 (Figure 1.4B). The 3 distinct 5' 
ends were shown to result from alternate promoter usage or alternate inclusion of exon 
3A. The Nl 5' end results from the inclusion ofexons lA, 2A, and 3A which gives rise 
to the MLKMCIRCLCLIGLQTVCGLFSCQITQ amino acid sequence. N2 results from 
the usage of ex on lA and 2A only, resulting in a ML-amino acid sequence. The usage of 
exon lB alone gives rise to the N3 5' end, which consists of the MAE-N-terminal amino 
acid sequence. 
In addition to the variation found within the 5' end of hmi-er 1, there is also 
variation found at the C terminal, or 3' end, of the gene as well. With the usage of 
alternative splicing or alternate polyadenylation signals (PAS) four 3' ends, a, bi, bii, and 
biii are produced (Figure 1.4B). The a C-terminus results from the a 3' end portion of the 
transcript and encodes a 23 amino acid domain, while the bi, bii, and biii 3' portions are 
predicted to produces the same 102 amino acid domain known as the /3 C-terminus. The 
difference in the amino acid sequences would suggest that both the a and /3 isoforms have 
two distinct functions. With the 3 distinct N termini (Nl, N2 and N3), in combination 
with the 2 possible C termini, it is predicted that 6 distinct hMI-ERl proteins are 
produced: Nla, Nl/3, N2a, N2/3, N3a and N3/3 (Paterno et al., 2002). 
" By comparing both hMI-ERl and XMI-ERl isoforms with other known proteins, 
a number of conserved functional domains were identified. The common internal 
sequence contains a highly acidic residue region, an ELM2 domain, and a signature 
SANT domain. As well, there is a proline rich motif, a LXXLL motif and a functional 
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nuclear localization signal (NLS), all of which are later described in full detail (Figure 
1.5). 
1.5.1 The Acidic Activation Domain 
At theN terminus ofhMI-ERl there are known to be four stretches of highly 
acidic regions encompassing amino acids 18-172, suggesting that hMI-ERl contains an 
acidic activation domain. Acidic amino acids are amino acids whose side chains can carry 
a negative charge at neutral pH, and include aspartic and glutamic acids. Acidic 
activation domains were first described as being present in the yeast GAL4 protein (Ma 
and Ptashne, 1987). GAL4 is a transcriptional activator of the genes GALl and GALlO. 
Both genes are required for galactose catabolism in the yeast Saccharomyces cerevisiae. 
Galactose catabolism is the process of breaking down galactose into a simpler 
component, called aldohexose galacto-hexose. Ma and Ptashne (1987) initially assayed 
the ability of various deletion mutants of GAL4 to activate transcription in yeast. The 
results revealed that the two regions ofGAL4 (residues 148-196 and 768-881), which are 
rich in acidic residues, play a very important role in transcriptional activation. In addition, 
further studies have also shown that acidic amino acids are indeed crucial for 
transcriptional activation. For example, Blair et al (1994) have shown that the potent C-
terminal activation domain of the protein RelA contains several acidic activation 
domains, and that the RelA activation domain is dependent on the acidic activator 
sequences. 
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Figure 1.5 Functional protein domains in both hMI-ERl isoforms. 
hMI-ER1a and hMI-ER113 consists of 433 and 512 amino acids respectively, as noted left 
of the schematic. At theN terminus, both hMI-ER1 isoforms contain four regions rich in 
acidic amino acids labeled as the acidic activation domain (18-172), an ELM2 domain 
(179-283), a signature SANT domain (287-332) and a PXXP motif C terminal to the 
SANT domain. As seen in the diagram, hMI-ER1a is distinct from the hMI-ERlB 
isoform at the C Termini. In addition, the LXXLL motif is found within the C-terminal 
region ofhMI-ERla, whereas the NLS is found within the C terminal region ofhMI-
ER113. 
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The stretches ofhighly acidic regions found in theN terminus ofMI-ER1, 
characteristic of acidic activation domains, were first studied in Xenopus and the 
transactivation potentials were tested. The results revealed that although full length XMI-
ERl did not activate transcription, the deletion construct harboring the first 3 acidic 
amino acid stretches (aa 1-98) stimulated transcription 80-fold (Paterno et al., 1997). It 
was therefore shown that XMI-ER1 contains an acidic activation domain, and that it has 
the potential to function in activating transcription. 
As previously mentioned XMI-ER1 and hMI-ER1 isoforms share 91% sequence 
similarity, therefore suggesting that hMI-ERl contains a putative acidic activation 
domain and may play a role in transcriptional activation. 
1.5.2 The ELM-2 Domain 
The ELM-2 Domain is found between amino acids 179-283 in both ofthe hMI-
ERl protein isoforms. ELM-2 gets its name from the &G1-27 and MTAl homology 
domain~, and was initially identified in a C. elegans protein known as EGL-27, as well 
as in the MTAl protein found in humans (Solari et al., 1999). The EGL-27 protein has 
been shown to play a fundamental role in developmental patterning. Like the MTAl 
p~tein, it is thought that EGL-27 plays a very important role in transcriptional regulation 
by regulating histone acetylation. The MTAl protein is a component of a protein 
complex with histone deacetylase and nucleosome remodeling activity and is therefore 
thought to play a role in repressing gene transcription. Interestingly, elevated expression 
levels of the human mtal gene occur in metastatic carcinomas (as reviewed in Nicolson 
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et al., 2003). It has recently been shown that hMI-ERl plays a role in repressing 
transcription by recruiting HDACl, a histone deacetylase, via its ELM2 domain (Ding et 
al., 2003). 
1.5.3 The SANT Domain 
The SANT domain, found C-terminal to the ELM2 domain and between amino 
acids 288-332 in hMI-ERl, was initially found in the proteins ~WI3, Ada2, N-CoR and 
IFIIIB, from which the name is derived. SWI3 and Ada2 are involved in transcriptional 
activation complexes, TFIIIB is found in RNA polymerase initiation complexes, while N-
CoR is involved in regulating nuclear hormone activity. Sequence alignment and 
secondary structure studies revealed a great deal of similarity between the SANT domain 
and the DNA binding domain (DBD) ofmyb related proteins. For instance, the Myb-
DBD consists of tandem repeats of three a helices arranged in a helix-tum-helix motif 
while the predicted secondary structure suggests the presence of three a helices in the 
SANT domain. The overall analysis suggests that the tertiary structure of the SANT and 
Myb-DBD are similar, and that SANT domain may be involved in transcriptional 
regulation via DNA binding and protein-protein interactions (as reviewed in Aasland et 
alr, 1996). The SANT domain is also found in the protein SMRT (silencing mediator for 
retinoid and thyroid receptors), which has been shown to play a major role in 
transcriptional and regulatory complexes. The SANT domains of both SMRT and N-
CoR interact with and activate histone deacetylases (HDACs) thereby inhibiting 
acetylation ofhistones and further repressing transcription (Guenther et al., 2001). 
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Recently, it has been shown that the SANT domain ofCoREST, a corepressor to the 
REST transcription factor, is responsible for interacting with HDAC (You et al., 2001). 
Similarly, the SANT domain has been shown to interact with GenS, the first histone 
acetyl transferase to be identified, and later found to be a subunit of the transcriptional 
regulatory complex SAGA in yeast. Further analysis revealed that effective histone 
acetylation by GenS requires the SANT domain of Ada2, further strengthens the idea that 
the SANT domain plays a role in transcriptional regulation (Sterner eta!., 2002). In 
addition, Ding eta!., (2004) showed that the SANT domain ofhMI-ER1 is important for 
binding Sp 1 and regulating its function. 
1.5.4 The Proline-Rich Region 
MI-ER1 also has a proline-rich motif(PXXP, where P represents the amino acid 
proline, and X represents any other amino acid), C terminal to its SANT domain. Proline-
rich motifs are regions that can bind to the Src homology 3 (SH3) domains 
(Alexandropoulos eta!., 199S). SH3 domains are one of the best characterized protein 
interacting modules that mediates protein-protein interactions and control signaling 
within the cell. By binding to proline- rich motifs, SH3 domains play critical roles in 
o~anizing protein complexes within the cell, bringing substrates to enzymes, and 
regulating enzymatic activity (Cohen eta!., 199S). 
The fact that MI-ERl contains a proline-rich motif suggests that MI-ERl may 
possibly function as a SH3 recognition motif. Furthermore, the presence of a PXXP 
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amino acid sequence suggests that MI-ERl may function in transcriptional regulation via 
protein-protein interactions. 
It has recently been shown that the overexpression of XMI-ERl during Xenopus 
embryonic development induces abnormalities involving truncations of the 
anteroposterior axis. A mutation in the first proline of the proline rich motif e65P) 
completely eliminated the effects seen (Teplitsky et al., 2003). The results demonstrate 
that the critical residue for XMI-ERl developmental effects is the amino acid 365P, found 
within the proline-rich region. 
1.5.5 LXXLL Motif 
Found in the C terminus ofhMI-ERla is an LXXLL motif, in which L represents 
leucine and X represents any amino acid. The LXXLL motifs can be found in many 
different nuclear hormone receptor co-activators and corepressors and have been shown 
to be required for the binding of the transcriptional regulators to the nuclear hormone 
receptors. 
Recently, an 8 amino acid sequence spanning positions -2 to +6, relative to the 
primary conserved leucine residue, has been defined as the minimal "core" LXXLL 
metif. In addition, it has been shown that differences in the minimal core region affect the 
selectivity and affinity of the transcription co-regulators to the nuclear hormone 
receptors. For instance, LXXLL motifs that contain a hydrophobic residue at the -1 
position and a non-hydrophobic residue at position +2 display a high affinity for steroid 
and retinoid receptors (Heery et al., 1997). hMI-ERla contains the minimal core LXXLL 
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motifwith a hydrophobic residue at the positions -1 and +2. Unlike the hMI-ERla 
isoform, there are no LXXLL motifs present in the hMI-ER113. 
1.6 Research Goals 
The presence of a SANT domain in hMI-ERl suggests that hMI-ERl might 
interact with HATs, as seen with the SANT domain of Ada2 (Paterno et al., 1998; Sterner 
et al., 2002), and may play an additional role in chromatin remodeling and transcription. 
Given that only the hMI-ER113 isoform contains a functional NLS and is localized in the 
nucleus, my goal was to determine ifhMI-ER113 interacts with CBP, to determine the 
domains responsible for any interaction, and to determine its effect on histone 
acetylation. 
Objective 1: Identification of CBP as a hMI-ER16 interacting protein. 
hMI-ER113 contains a SANT domain which is also found in many known 
transcriptional regulators, such as Ada2. Recent studies have shown that the SANT 
domain of Ada2 is responsible for the interaction with GenS, a well known histone 
acetyltransferase. Therefore, my first objective was to determine ifthere was an 
interaction between hMI-ER113 and CBP in vitro and in vivo. With the evidence that CBP 
plays a very important role in transcription, as well as previous studies that indicate hMI-
ERl levels are increased in breast tumor cells and tissues (Paterno et al., 1998), 
identifying the interaction between the two proteins are of extreme importance. Initially, 
GST pull downs were completed with GST -hMI-ER113 and 35S-labelled CBP to 
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determine if an interaction occurs in vitro. To further determine if an interaction occurs in 
vivo, cotranfections of both hMI-ERlB and CBP plasmids were performed in HEK 293 
cells. 
Objective 2: Identification of the CBP domains responsible for the interaction. 
In an attempt to further characterize the domains of CBP required for the 
interaction with hMI-ERlB, further in vitro and in vivo experiments were conducted. CBP 
deletion constructs were made and GST pull down assays were performed using GST-
hMI-ERlB and 35S-labelled CBP Br-Q and CBP RID-Br deletion constructs. In addition, 
cotransfections of both hMI-ERlB and CBP deletion constructs were performed in HEK 
293 cells. 
Objective 3: Identification of the region of hMI-ERlB responsible for the interaction 
with CBP. 
In addition to characterizing the region of CBP responsible for the interaction 
with hMI-ERlB, another goal was to identify the region ofhMI-ERlB responsible for the 
interaction with CBP. GST-hMI-ERlB deletion constructs were cloned that contained 
different regions of the acidic amino acid regions, and solely the ELM2 domain. Other 
deletion constructs previously made include those which harbored the SANT domain or 
the SANT domain including the C terminus. GST pull down assays were performed using 
the GST-hMI-ERl deletion constructs and 35S-labelled CBP Br-Q protein. 
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Objective 4: Determination of the effects of hMI-ERlB on histone acetylation and 
possible mechanisms of action. 
With the recent evidence that the SANT domain of Ada2 affects the histone 
acetylation activity of GenS, the next goal was to investigate whether hMI-ERlB could 
also affect CBPs ability to acetylate histones. Histone acetyltransferase assays were 
performed in vitro with hMI-ERlB and CBP proteins expressed in HEK 293 cells. In 
addition, HAT assays were also carried out using the CBP Br-Q and hMI-ERlB protein 
expressed in these cells. 
HAT activity may be regulated by altering substrate recognition and/or the 
enzymatic activity of histone acetyltransferases. To determine the mechanism by which 
hMI-ERlB inhibits histone acetylation, further HAT assays were carried out to eliminate 
the possibilities that hMI-ERlB functions by histone "masking" or by selectively binding 
to inactive CBP. 
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Chapter 2: Materials and Methods 
All the vectors used in this project are listed in Table 2.1. The description of each 
vector is also included. 
Table 2.1: List of the plasmids used, a brief description, and the tags they include. 
Plasmids Used Construct Description 
pGEX-4T-1 Glutathione S-transferase gene fusion vector used in the 
expression, detection and purification of GST fusion proteins 
in bacteria (Pharmacia, Biotech). 
pCS3 +MT Mammalian expression vector with 6 N-terminal myc tags. 
Myc epitopes contains amino acid residues 
MEQKLISEEDLNE and recognized by anti-myc antibody. 
A kind gift from David Turner. 
pCMV-Tag2 Mammalian expression vector with 1 N-terminal flag tag. 
Flag epitope contains amino acid residues DYKDDDDK and 
is recognized by anti-flag antibody (Stratagene). 
pRC/RSV Mammalian expression vector with enhancer-promoter 
sequences from the Rous sarcoma virus long terminal repeat 
(RSV LTR) (Invitrogen, Inc.). A kind gift from Roland 
Kwok 
pCDNA3 Mammalian expression vector (Invitrogen, Inc.) 
pCR2.1 Bacterial expression vector used forT A cloning (Invitrogen, 
Inc.} 
pCR3.1 Mammalian expression vector, used for T A cloning 
(Invitrogen, Inc.) 
32 
2.1 Plasmids and constructs 
2.1.1 Generation of flag tagged CBP fusion constructs 
2.1.1.1 PCR 
The pRc/RSV vector, containing the complete coding sequence of full length 
mouse CBP [accession number NM_ P45481] with anN-terminal Bluescript KS 
polylinker and a C terminal HA tag, was a kind gift from Dr. Roland Kwok. The entire 
coding sequence was excised with Hindiii and Not! restriction enzymes (Invitrogen, Inc., 
Burlington, Ontario, Canada) and ligated into the Hindiii and Not! site of the pcDNA3 
vector (Invitrogen, Inc). For all CBP constructs designed, full length CBP with the 
Bluescript KS polylinker and aHA tag in pcDNA3 was used. The polymerase chain 
reaction (PCR) was used to amplify DNA sequences in vitro for the production of CBP 
RID-Br, and CBP Br-Q constructs. 
For the generation of CBP RID-Brand CBP Br-Q constructs, different regions of 
CBP were amplified by PCR with CBP specific primers containing BamBI 5' and 3' 
recognition sites (ggatcc underlined in primer sequence, Table 2.2) to facilitate cloning. 
The PCR master mix was prepared as per the Platinum Taq DNA polymerase 
manufacturer's instructions (Invitrogen, Inc). In general, IX high fidelity PCR buffer was 
mt.Ked with 0.2mM of each dNTP (Invitrogen, Inc.), 2mM MgS04 (Invitrogen, Inc.) and 
deionized water. Platinum Taq high fidelity polymerase (Invitrogen, Inc.) was then added 
to the tube. The contents of the tubes were mixed, centrifuged, and incubated in a thermal 
cycler at 94°C for 5 minutes to denature the template and activate the enzyme. 30 cycles 
of the PCR amplification steps were performed as follows: 94°C for 30 seconds for 
33 
denaturation, 55°C for 30 seconds for primer annealing, 68°C for 4 minutes for primer 
extension, 1 cycle of 72°C for 10 minutes and 30°C for 1 second. Finally, the PCR 
products were treated with Taq polymerase (1.0 units; Invitrogen, Inc) at 72°C for 10 
minutes to create a TA-overhang for use in Topo cloning (Invitrogen, Inc). Upon 
completion, the samples were analyzed by 1% Tris borate/ EDTA (TBE) gel 
electrophoresis and visualized by ethidium bromide staining. 1% TBE agarose gels were 
made up of 1% agarose (Invitrogen, Inc) in 1.0X TBE buffer (Table 2.3). 
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Table 2.2: PCR primer pairs used for preparing pCMV-Tag2B-CBP constructs. 
Construct Fonvard Primer Reverse Primer 
CBP RID-Br 5' -GGGGATCCATGGCCGA 5 '-CGGGATCCCTACAT AAGTGC 
aa 1-1096 GAACTTGCTGGACG -3' CTGGCGTAGCTCCTCG -3' 
CBP Br-Q 5 '-GGGGATCCGCACTTATG 5 '-CCGGATCCCTACAAACC 
aa 1094-2441 CCAACTCTAGAAG -3' CTCCACAAACTTTT -3' 
The BamHI recognition sites are underlined. 
Table 2.3: Components ofTBE 
lOX Stock lX Stock 
Tris Base (Fisher) 108g 10.8g 
Boric Acid (Fisher) 55g 5.5g 
EDTA (0.5M, pH 8.0) Fisher 40ml 4ml 
dHzO Up tolL Up tolL 
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2.1.1.2 Ligation of PCR Products into pCR 2.1 
Immediately after the treatment with Taq polymerase, the PCR products were 
ligated into pCR2.1-Topo according to the manufacturer's protocol (Topo TA cloning, 
Invitrogen, Inc). Briefly, 1111 ofPCR product was added to 1~-Ll1M NaCl, 0.5~-Ll of 
pCR2.1-Topo (Invitrogen, Inc) and 3.5~-Ll of deionized water. All samples were mixed 
gently, placed at room temperature for 5 minutes and then placed on ice. Transformations 
were then performed using One Shot competent cells provided with the T A Cloning kit 
(Invitrogen, Inc). The transformation involved adding 2111 of the Topo Cloning reaction 
into a vial of One Shot chemically competent E. Coli. The mixture was gently mixed and 
placed on ice for 5 minutes. The cells were then heat shocked at 42°C for 30 seconds and 
immediately transferred to ice for 2 minutes. 250~-Ll SOC medium (Invitrogen, Inc.) was 
added to the sample and then shaken at 37°C for 1 hour at 225 rpm. 20 and 50~-Ll of the 
reaction were plated on pre-warmed luria-broth (LB) +ampicillin agar plates (5g 
peptone, 2.5g yeast extract, 5g NaCl, 7.5g Agar, 500mL dH20; autoclaved; 50 11g/ml 
ampicillin) and grown overnight at 3 7°C. 
After transformation, colonies of competent E. Coli containing desired plasmids 
were inoculated in LB medium (5g peptone, 2.5g yeast extract, 5g NaCl, 500ml dH20; 
aut'oclaved) containing 50 11g/ml ampicillin, and to grow overnight at 37°C, shaking at 
225 rpm. 
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2.1.1.3 Plasmid Isolation 
DNA purification using the Plasmid Mini Kit (Promega, Ottawa, Ontario, 
Canada) was carried out as per the manufacture's instructions. To determine the 
concentration of the isolated plasmid DNA, agarose gel electrophoresis and 
spectrophotometry were performed as described in 2.1.1.2. 
2.1.1.4 Digestion and purification of inserts from pCR2.1 and pcDNA3 
To isolate the CBP RID-Brand CBP Br-Q inserts, the pCR2.1 vectors containing 
the inserts were digested with the BamHI restriction enzyme (Invitrogen, Inc.). Likewise, 
CBP full length was obtained by initially removing it from pcDNA3 following the same 
protocol. The pCMV Tag 2B vector (Stratagene, La Jolla, California, U.S.A.) used as the 
ligating vector for all CBP constructs was also digested with BamHI. The total amount of 
DNA used in each case was 1 OJ.Lg, and the final volume was made up with deionized 
water. The samples were mixed briefly and incubated at 37°C for 1 hour as directed. 
After 1 hour, the pCMVTag2B vector was treated with calf intestinal alkaline 
phosphatase (ClAP; Invitrogen, Inc.) for 10 minutes at 3 7°C. ClAP catalyzes the 
hydrolysis of 5' phosphate groups from DNA, RNA and both ribo-and 
dooxyribonucleoside triphosphates. The digested inserts and vector were loaded on a 1% 
Tris-acetate/ EDTA (TAE) gel. 1% T AE agarose gels were made up of 1% agarose 
(Invitrogen, Inc) in l.OX TAE buffer (Table 2.4). 
The gel was visualized under low UV light and the area containing desired DNA 
was removed. Ultrafree DNA purification filters (Millipore Corporation, Billerica, 
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Table 2.4: Components ofTAE 
SOX Stock IX Stock 
Tris Base (Fisher) 242g 4.84g 
Glacial Acetic Acid (Fisher) 57.lml 1.14ml 
NazEDTA.dHzO 37.2g 0.744g 
dHzO Up tolL Up tolL 
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Massachusetts, U.S.A.) were then used to purify the isolated DNA, as per manufacturer's 
instructions. 
2.1.1.5 Ligation of CBP, CBP RID-Brand CBP Br-Q into pCMV-Tag2B. 
The CBP, CBP Rid-Brand CBP Br-Q inserts were ligated into the pCMV-Tag 
2B vector (Stratagene) using T4 DNA ligase HC, according to the manufacturer's 
protocol (Invitrogen, Inc). 5X ligase reaction buffer (Invitrogen, Inc.), lOmM rATP 
(Promega), and deionized water were added. The mixture was placed at l4°C overnight. 
Later, 2J.~.l ofthe ligation mix was transformed into XLl-Blue supercompetent cells 
(Stratagene). The transformed XLl-Blue cells were plated on LB + 30 J.l.g/mL kanamycin 
and incubated overnight at 37°C at 225 rpm. 
PCR was performed to identify positive trans formants. For the CBP/ pCMV 
Tag2B, CBP RID- Br/pCMV Tag2B and CBP Br-Q/ pCMV Tag2B constructs, a reverse 
vector primer (T7) made specific for the T7 promoter region ofthe pCMV Tag2B vector 
was used. In addition, a specific primer made for the 5' region of each construct was 
used. The forward primer (CBP 3) was used as an internal primer for both CBP and CBP 
Br-Q, and CBP 1 was used as a 5' primer for CBP RID-Br (Table 2.5). The PCR master 
m!x was prepared as per the Taq DNA polymerase manufacturer's instructions 
(Invitrogen, Inc). In general, lX PCR buffer was mixed with 0.8M dNTP mixture 
(Invitrogen), 2mM MgCLz (Invitrogen, Inc.), 0.2mM of each set of the appropriate 
primers mentioned above, deionized water, and Taq DNA polymerase. The tubes were 
first placed in a thermal cycler at 94°C for 5 minutes. 30 cycles ofPCR amplification 
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steps were performed as follows: 94°C for 1 minute, 55°C for 1 minute, and 72°C for 1 
minute. 1 cycle of 72°C for 10 minutes and 30°C for 1 second was then performed. The 
samples were run on a 1% TBE agarose gel and visualized under ultraviolet light. The 
positive transformants were used to inoculate LB + kanamycin and shaken at 225 rpm 
overnight. The next day the plasmids were isolated using the mini-prep kit, as described 
in 2.1.1.3. All sequences were verified by DNA sequencing. 
2.1.1.6 DNA Sequencing 
All ligated segments of the CBP constructs were sequenced using the United 
States Biochemical (USB, Cleveland, Ohio, U.S.A.) sequenase version 2.0 DNA 
sequencing kit. In general, 2 ~1 of0.2N NaOH/ 0.2N EDTA was added to 5 ~g of the 
previously isolated plasmid DNA. The mixture was then incubated at 37°C for 20 
minutes. After the incubation, the mixture was precipitated with 21-11 3M sodium acetate 
(NaOAc, pH 5.2) and 60~1 of95% ethanol. The mixture was placed at -70°C for 15 
minutes, and centrifuged at full speed for 20 minutes. The supernatant was discarded and 
the pellet was washed with 70% ethanol, dried in a dessicator and finally resuspended in 
71!1 water . 
.,. The second step of DNA sequencing involves the annealing of the appropriate 
primers to the DNA samples. This step involves the addition of sequencing reaction 
buffer and the corresponding primer to each DNA sample. To sequence all the CBP 
constructs, a 5' forward pCMV-Tag2B vector primer (T3) and a reverse primer (T7) were 
used (Table 2.5). The components were then mixed and heated at 65°C in a beaker for 2 
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Table 2.5: Primers used to analyze and sequence CBP/ pCMV-Tag2B constructs 
Primer Forward or Primer Sequence 
Name Reverse Primer 
T7 Reverse 5 '-GGTACCT AA TACGACTCACT AT AGGG-3' 
CBP 1 Forward 5 '-GGGGATCCATGGCCGAGAACTTGCTGGACG-3' 
CBP 3 Forward 5 '-GGGGATCCGCACTTATGCCAACTCTAGAAG-3' 
T3 Forward 5 '-GCTCGAAA TT AACCCTCACT AAAG-3' 
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minutes, slowly cooled to <35°C during 15-30 minutes, centrifuged briefly and chilled on 
ICe. 
Next, the annealed primer-DNA was mixed with 0.1M dithiothreitol (DTT), 
diluted labeling mix/ dGTP, 35S-dATP (NEN Technologies, Zaventem, Belgium), 
enzyme dilution buffer, and sequenase, and then placed at room temperature for 5 
minutes. 3.5~1 of the labeled mix was then added to the four nucleoside phosphates 
(ddATP, ddGTP, ddCTG, ddTTP) that were previously heated for 3 minutes at 37°C. The 
reaction mixture was heated for an additional 5 minutes at 37°C. 4~1 of the stop solution 
was then added to stop the reaction. The samples were heated at 75°C for 2 minutes and 
loaded on a polyacrylamide sequencing gel. 
6% polyacrylamide sequencing gels were prepared using the following 
components: 100 ml of a previously prepared sequencing mix [containing 48g Urea 
(Fisher, Nepean, Ontario, Canada), 15ml 40% bis acrylamide (BioRad, Mississauga, 
Ontario,Canada), 10ml10X TBE and 35ml water], 440 ~1 of 10% ammonium persulfate 
and 44~1 TEMED (BioRad). Before loading, the prepared DNA sequencing gel was first 
warmed up to about 45°C. 4~1 of each pre-warmed sample was loaded per well. The gel 
was run at 60V for approximately 2 hours and was fixed with 1 0% glacial acetic acid/ 
1 ()jl/o methanol (Fisher), exposed onto film overnight and then developed. 
Once the DNA sequence was verified, the previously mini-preped samples were 
transformed into XLl-Blue supercompetent cells as previously described. To isolate 
plasmid DNA from the cultured bacterial cells, the HiSpeed Plasmid Midi Kit (Qiagen, 
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Mississauga, Ontario, Canada) was used. The concentration of the isolated DNA was 
determined by agarose gel electrophoresis and spectrophotometry. 
2.1.2 CS3MT and CS3MT-hmi-erl 6 
CS3+MT vectors (a kind gift from David Turner, University of Michigan) were 
engineered to contain full length hmi-erlj3 (Ding et al., 2003). The entire coding 
sequence of hmi-erlj3 (accession number AF515447) was amplified using specific 5' and 
3' primers as described in Ding et al., 2003. The PCR fragments were then inserted into 
the Bglii site of CS3+MT plasmid. 
2.1.3 GST-hmi-erljJ full length and GST-hmi-erljJ deletion constructs 
GST -hmi-er lj3 and the hmi-er lj3 deletion mutants fused to GST, except for the 
deletion mutant hmi-er Jj3 aa 1-179 described in 2.1.4, were constructed by Z. Ding in our 
laboratory (Ding et al., 2003). 
2.1.4 G(meration of pGEX-4T-1-hmi-erljJ aa 1-179 
2.1.4.1 PCR 
1" To produce pGEX-4T-l-hmi-erl aa 1-179, the CS3-MT- hmi-erlj3 plasmid was 
used. The fragment encoding the amino acid residues 1-179 was amplified using a 
forward hmi-erl primer made specifically for the 5' region of hmi-erl (Her34K) and a 
reverse primer specific for the 3' region of hmi-erl aa 1-179 sequence (mi-her1 TlOO; 
Table 2.6). The samples were initially incubated at 94°C for 2 minutes to denature the 
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template and activate the enzyme. 30 cycles ofPCR amplification steps were performed 
as follows: 94°C for 30 seconds for denaturation, 55°C for 30 seconds for primer 
annealing, and 68°C for 36 seconds for primer extension. 1 cycle of 72°C for 10 minutes 
and 30°C for 1 second was then performed. Finally, the PCR products were treated with 
Taq polymerase (1.0 units; Invitrogen, Inc) at noc for 10 minutes to create a TA-
overhang for use in Topo cloning (Invitrogen, Inc). 101-11 of each amplification product 
was analyzed by 1% TBE agarose gel electrophoresis and visualized by ethidium 
bromide staining. 
2.1.4.1 Ligation of PCR Products into pCR 3.1 
The PCR products were ligated into pCR 3.1 according to the manufacturer's 
protocol. All components provided by the T A cloning kit (T A cloning, Invitrogen, Inc) 
were used. 12.7 ng of the PCR product added to the following: lOX ligation buffer, pCR 
3.1 vector (30ng/!ll), T4 DNA ligase (4units/ !ll) and deionized water. The mixture was 
incubated overnight at l5°C. The next day, transformations were performed using 
XLlBlue-supercompetent cells (Stratagene). The entire reaction was later plated on LB + 
ampicillin (50 !lg/ml), inverted and incubated overnight at 37°C. 
~ The next step was to screen the bacterial colonies for the uptake of the ligated 
DNA. A 3' reverse pCR 3.1 vector primer (pCR 3.1) and a 5' forward primer (Her34K) 
were used (Table 2.6). The PCR master mix was made up as described in section 2.1.1.6 
and the samples were initially incubated at 94°C for 3 minutes. 30 cycles ofPCR 
amplification steps were performed as follows: 94°C for 45 seconds, 55°C for 30 seconds, 
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Table 2.6: PCR primers used to construct pCR 3.1-hmi-erlfl aa 1-179 and pGEX-
4T-1-hmi-erljJ aa 1-179. 
Primer Name Reverse or Forward Primer Sequence 
Primer 
pCR 3.1 Reverse 5' CTGATCAGCGGGTTT AAACGGG-3' 
Her34K Forward 5 'CACCATGGCGGAGCCATCTGTTGAA TC-3' 
pGEX 1.1 Forward 5 'GGGCTGGCAAGCCACGTTTGGT -3' 
mi-her1 TlOO Reverse 5 'GCCCTACCAGTCTTCTGATGGAA T -3' 
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and noc for 1 minute and 30 seconds. 1 cycle of72°C for 10 minutes and 30°C for 1 
second was then performed. The samples were run on a 1% TBE agarose gel and 
visualized under ultraviolet light. Colonies that tested positive were used to inoculate LB 
+ ampicillin and allowed to shake at 225 rpm, overnight. The next day the plasmids were 
isolated using the mini-prep kit, described in 2.1.14, and then prepared for restriction 
enzyme digestion. 
2.1.4.2 Digestion and purification of insert from pCR 3.1 
To isolate the hmi-er 1 aa 1-179 insert, both the pCR3 .1 vector containing the 
insert and the pGEX 4T-l vector (Pharmacia, Biotech, Piscataway, New Jersey, U.S.A) 
were digested with the EcoRI restriction enzyme (Invitrogen, Inc.) as previously 
described. 
2.1.4.3 Ligation of hmi-er11-179 into pGEX-4T-1 
After purification, the insert was ligated into the pGEX-4T -1 vector, transformed, 
and screened for positive colonies. In all incidences the same protocol was followed as in 
section 2.1.1.3, except ampicillin was added to the LB medium instead of kanamycin. As 
we11, the primers used to screen for positive colonies included a forward primer specific 
for the 5' region ofpGEX-4T -1 (pGEX 1.1) and a reverse primer (mi-her1 T100) specific 
for the 3' region of hmi-er 1 aa 1-179 sequence (Table 2.6). 
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Following colony screening, the plasmid was isolated using the mini-prep kit. To 
confirm the nucleotide sequences of the isolated plasmid DNA, DNA sequencing was 
performed, as in section 2.1.4.4. 
2.2 In vitro Transcription-Translation 
In order to perform GST pull down assays, in vitro translations were performed 
using the TnT® Couple Reticulocyte Lysate System (Promega). The following reaction 
components, provided in the kit, were mixed for a 50 ).tl reaction : 25).tl TnT® Rabbit 
Reticulocyte Lysate, 2 ).tl TnT Reaction Buffer, 1 ).tl of the appropriate TnT® RNA 
Polymerase (SP6, T3 or T7), 1 ).tl amino acid mixture, minus methionine, and 1 ).tl of 
ribonuclease inhibitor [RNA Guard (27-0815-01); Amersham Biosciences]. 66.6 ).tCi of 
[35S] methionine and DEPC water was then added to make up to a final volume of 50).tl 
master mix. This master mix was equally distributed to all samples with the 
corresponding plasmid DNA (1).tg). The samples were analyzed using tricholoroacetic 
acid (TCA) precipitation assays and then stored at -70°C for future use. 
After completion of the in vitro transcription-translation reaction, TCA 
precipitation assays were conducted in order to analyze the results of the translation. TCA 
pn!!cipitation assays provide a numerical value for the amount of protein made based on 
the amount of e5S]-methionine incorporated into the protein. To perform this assay 2 Ill 
of the reaction was removed and bleached with 1M NaOH/2% H20 2, vortexed briefly and 
incubated at 37°C for 10 minutes. 900 Ill of ice-cold 25% TCA/2% casamino acids 
(Merck) was then added to precipitate the translated product. The mixture was placed on 
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ice for 30 minutes. The precipitate was then collected on a filter paper (Fisher) as 
follows: 1 ml of each sample was filtered using a vacuum flask and then washed with 5% 
TCA. Approximately 3mls of 95% ethanol was added to dry the filter paper. To 
determine e5s] methionine incorporation, the filter was placed in 5ml Biodegradable 
Counting Scintillant (Amersham) and analyzed in a Beckman S3801 Scintillation 
Counter. 
2.3 GST Pull Down Assays 
2.3.1 Preparation of Glutathione Sepharose 4B Matrix 
Glutathione Sepharose 4B matrix (Pharmacia Biotech) was prepared as per 
manufacturer's instructions. Approximately 1.33mls of the original 75% slurry was 
removed and transferred to a 15ml conical tube (Fisher). The matrix was centrifuged at 
500 x g for 5 minutes, and the supernatant was carefully removed. The matrix was then 
washed with lOml of cold lX phosphate buffered saline (PBS), mixed, and centrifuged 
again at 500 x g for 5 minutes. After the supernatant was removed, lml of lX PBS was 
added which resulted in a 50% slurry. The beads were mixed well before use and stored 
with 0.02% azide at 4°C. 
2.3.2 GST Fusion Protein Production 
To produce GST fusion protein, lOng of the pGEX-4Tl plasmid was added to 
lOO!J.l ofBL21 Codon Plus RP competent E. coli cells (Stratagene). The sample was 
placed on ice for 30 minutes and then heat shocked for 45 seconds at 42°C. 2501J.l ofLB 
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was added to the reaction mixture and shaken at 3JOC for 1 hour. After shaking, all of the 
reaction mixture was plated on LB ampicillin plates and stored at 37°C overnight. The 
following day, one colony from each plate was allowed to grow in 5mL ofLB medium 
with 50).lllml ampicillin, while shaking overnight at 37°C. The next day, 2mls of the 
overnight culture was added to 250ml LB medium with 50).lg/ml ampicillin and allowed 
to grow while shaking at 37°C for approximately 3.5 hours. The optical density (OD) of 
the culture was measured at a wavelength of 600nm in a spectrophotometer (Beckman, 
Du-64). The culture was allowed to grow until it reached an OD of0.6-0.8 after which 
25).ll of 1M IPTG (isopropyl-B-D-thiogalactopyranoside; Invitrogen, Inc) was added and 
shaken at 37°C for 4 hours. The culture was poured into a 250ml Nalgene polypropylene 
bottle and centrifuged at 4000 rpm for 15 minutes in a Sorval centrifuge. All the liquid 
was drained and the pellet was resuspended in 5ml ice cold lX PBS (8.0g NaCl, 0.2g 
KCl, 0.24g KHzHP04.7H20, lL H20; autoclaved) + 25).ll 0.2M Phenylmethylsulfonyl 
Fluoride (PMSF; Sigma, Oakville, Ontario, Canada) and 50).ll 1 OOX protease inhibitors 
[PI; lOmg aprotinin (Sigma), lOmg leupeptin (Sigma), and 50mg nor-P-Tosyl-L-Lysine 
Chloromethyl Ketone (Sigma) in the total volume of lOml dH20]. The solution was 
placed into a 15ml conical tube whereby the cells were lysed by mild sonication for 1 
mmute using a sonicator (Virsonic Cell Disrupter, 16-850). Following sonication, SOO).ll 
of 10% Triton X-100 (Sigma) was added to the mixture. The mixture was then 
transferred to a 30ml Corex glass tube and centrifuged at 6000 rpm in a Sorvall RC-SB 
centrifuge for 20 minutes. The supernatant was removed from the corex tubes and placed 
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at -70°C. GST fusion protein expression levels and purity was checked by SDS-
polyacrylamide gel electrophoresis (PAGE). 
2.3.3 GST Pull Down Assays 
For each GST pull down assay, 501J.l of GST Sepharose 4B beads was used for 
each individual reaction. The beads were then washed twice with 5001J.l of GST pull 
down buffer [20mM Tris-HCl, pH 7.5, 150 mM NaCl, 1mM EDTA, 10% Glycerol, 0.2% 
Nonidet P-40 (NP-40), 1X Protease Inhibitor (PI), 0.5% Bovine Serum Albumin (BSA)]. 
After subsequent washes, beads were suspended in GST pull down buffer (minus BSA) 
with the indicated GST fusion protein, and rotated for 1 hour at 4°C. Following 
incubation, unbound proteins were removed from the beads by washing the samples five 
times with 5001J.l of GST pull down buffer and resuspended in 5001J.l GST pull down 
buffer (minus BSA). Once resuspended, 100,000 counts per minute (cpm) of the 
appropriate 35S labeled in-vitro transcription and translation proteins (Flag tagged CBP, 
Flag tagged CBP Br-Q, and Flag tagged CBP Rid-Br) were added. With the addition of 
the 35S labeled protein, the samples were further rotated at 4°C for 2 hours. Following the 
rotation, the beads were washed three times with 500!-ll GST pull down buffer (minus 
B9-A), twice with 5001J.l of GST pull down buffer (minus NP40; interferes with SDS-
PAGE) and twice with 150mM NaCl. After washing, 301J.l of2X SSB (SDS sample 
buffer) was added to each sample and the sample run on a 8% SDS-PAGE at 30mA for 
approximately 1hour and 20 minutes. Input lanes contained 1/10 volume ofthe indicated 
TNT used for each reaction. The gel was then fixed in a fixative solution ( 45ml Methanol 
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(Fisher), 1 Oml Glacial Acetic Acid (Fisher), 45ml dH20) for 15 minutes, shaking at room 
temperature. The gel was then destained (20ml Methanol (Fisher), 6ml Glacial Acetic 
Acid (Fisher), 74ml dH20), shaking at room temperature for 15 minutes. Finally, the gel 
was placed in Amplify solution (Amersham) for 15 minutes, dried and visualized using 
autoradiography. 
2.4 Cell Culture 
Transformed human embryonic kidney cells (HEK 293), obtained from American 
Tissue Culture Collection, were cultured in Dulbecco's Modified Eagle's medium 
(DMEM; Hyclone) with the addition of7.5% Calf Serum (CS; Invitrogen, Inc.) and 2.5% 
Fetal Bovine Serum (FBS; Invitrogen, Inc.). The cells were cultured in a 37°C incubator 
with 10% COz. 
2.5 Transfections 
18 hours prior to transfection, approximately 5.0 x 105 HEK 293 cells/well were 
seeded. The following plasmids were used in co-transfections experiments: pCMV 
Tag2B CBP, pCMV Tag2B CBP Br-Q, pCMV Tag2B CBP Rid-Br, CS3MT, and 
Ci3MT-hMI-ERI.f3. Cells were cotransfected with l.5J.lg ofplasmid DNA by 
Lipofectamine Plus reagent (Invitrogen, Inc.) according to supplier's protocol. Briefly, 
1.5 J.lg of plasmid DNA was incubated with 6 Ill Lipofectamine and 6 J.ll Plus reagent in 
the total of200 111 serum-free medium at room temperature for 30 min. The mixture was 
added to cells previously seeded in 6-well plates containing 800 111 of serum-free medium 
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and incubated at 37°C for 4h, following which serum-free medium was replaced by 
DMEM + 7.5% CS + 2.5% FBS medium. 
2.6 Protein Extracts and Immunoprecipitation 
Total cellular extracts were analyzed to ensure successful transfections. 
Approximately 48 hours after transfection, the transfected cells were washed with 2ml 
IX PBS. 200 111 of 1.5X SSB (without bromophenol blue) was added to each well 
containing the transfected cells. The cells were passed through a syringe approximately 
I5-20 times. After centrifugation at I6,000 x g, 4°C for 5 minutes, the supernatant was 
removed, placed in a new I.5ml tube, and placed at -20°C until ready for use. 
The samples ready for immunoprecipitation (IP) were washed with 2ml1X PBS. 
1ml of IX Triton Cocktail (IOmM Tris pH 7.5, 1% Triton X IOO, 10mM EDTA, 0.02% 
Sodium Azide, dH20) mixed with 1 OOX PI was then added to the samples. The cell 
lysates were collected as previously described. Either the anti-flag monoclonal antibody 
(1 :750; F-3165, Sigma) or the anti-myc monoclonal antibody (1: 100; 9EIO, 
Developmental Hybridoma Bank) was added to the cell lysate and incubated overnight 
while rotating at 4°C. 
"' Following the overnight incubation, 50!11 of a 50% slurry of protein G beads 
(Amersham) was added to the tubes and rotated for an hour at 4°C. Following the 
incubation the beads were washed twice with Iml IX Triton Cocktail+ IX PI, and three 
times with Iml150mM NaCl. Beads were then resuspended in 35jll2X SSB containing 
bromophenol blue. The samples were boiled for 4 minutes, vortexed, centrifuged briefly 
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and loaded on an 8% SDS-PAGE. Gels were run for approximately Ih20min to allow full 
separation of protein components. The gels were agitated in three washes of IX transfer 
buffer [200ml5X Stock buffer (60.54g Tris, 288.4g glycine, 3L dHzO) + 200ml 
methanol, 600ml dH20] for IS minutes. Proteins were then transferred onto a Hybond-
ECL nitrocellulose membrane (Amersham) for 2 hours at 60 V. The membrane was then 
" 
blocked for 2 hours at room temperature in 5% skim milk/ IX TBS-T (20mM Tris pH 
7.6, 137mM NaCl, 0.1% Tween-20, dH20). 
2.7 Western blotting 
Western blot (WB) analysis was performed by incubating the membrane 
overnight with either the anti-flag antibody (1 :2000) or anti-myc monoclonal antibody 
(1:100) in 5% skim milk/IX TBS-T at 4°C. The next day the membrane was washed with 
IX TBS-T for 1 hour at room temperature, followed by incubation in sheep anti-mouse 
conjugated to Horseradish Peroxidase (I :3000) in 5% skim milk/lX TBS-T for I hour at 
room temperature. Finally, the membrane was washed 4-5 times with lX TBS-T for I 
hour at room temperature and then analyzed using the ECL Plus Detection Kit 
(Amersham). The membrane was exposed to ECL Hyperfilm (Amersham). 
2.8 Histone Acetyltransferase Assays 
Histone acetyltransferase assay was used to detect in vitro HAT activity. HEK 
293 cells were first transfected with the appropriate construct(s). After 48 hours, the 
transfected cells were lysed with IX HAT assay IP buffer (50mM Tris HCl pH 7.5, 
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150mM NaCl, 10% glycerol, 1% Triton X-1 00, dH20), followed by protein extraction and 
immunoprecipitation as described in section 2.6. The samples were incubated with 
protein G beads and washed three times with 1ml1X triton cocktail (10mM Tris HCl pH 
7.5, 1% triton, 10mM EDTA, 0.02% azide, dH20), and twice with 1ml 1X HAT assay 
buffer (50mM Tris HCl pH 7.5, 10% glycerol, 1mM DTT, 300nM TSA, dH20). 301J.l of 
HAT master mix [1~J.g/~J.l histone biotinylated H4 peptide (Upstate Biotechnology), [1-
14C] Acetyl-coenzyme A (Amersham, 10~-LCi), dH20, 300nM Trichostatin A (TSA), 2X 
HAT assay buffer] was then prepared and added to each sample. The samples were 
incubated for 45 minutes in a waterbath at 30°C. The HAT master mix was also added to 
the appropriate TNT samples as a control. 
After the incubation, the samples were centrifuged for 30 seconds and the 
supernatant containing acetylated histones was isolated. The remaining mixture was 
washed again with 70 ~J.llX HAT assay buffer and pooled with the previously isolated 
supernatant, to ensure that the maximum amount of acetylated histone samples was 
obtained. 20 ~J.l of prepared streptavidin beads (Pierce) was added to each sample and 
rotated for 30 minutes at 4°C. The samples were then washed twice with 1ml RIPA 
buffer (50mM Tris pH 7.5, 150mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, 
lmM EDTA, dHzO) and once with IX HAT assay buffer, followed by resuspension in 
IOO~J.l of 1X HAT assay buffer. Finally, 5mls of biodegradable counting scintillant 
(Amersham) was added and the samples were analyzed by a scintillation counter 
(Beckman S3801). 
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Chapter 3: Results 
To simplify the description of the results, the names of all constructs used are 
abbreviated. They are listed in Table 3.1 below. 
Table 3.1: A list of all constructs used and their abbreviated name. 
Constructs Used Abbreviated Name: 
pGEX-4T-1- hmi-erlj3 GST B 
pGEX-4T-1 GST 
pCMV-Tag2B flag 
pCMV-Tag2B-CBP CBP 
pCMV-Tag2B- CBP Rid-Er Rid-Br 
pCMV-Tag2B- CBP Br-Q Br-Q 
pCS3 + MT- hmi-er 1}3 B· 
pCS3 +MT myc 
pGEX-4T-1- hmi-erl aa 1-283 1-283 
pGEX-4T-1- hmi-erl aa 164-283 164-283 
p~EX-4T-1- hmi-erl aa 287-512 287-512 
pGEX-4T-1- hmi-erl aa 1-179 1-179 
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3.1: hMI-ER1B interacts with CBP in vitro 
To determine ifhMI-ERlB interacts with Creb Binding Protein (CBP), GST pull 
down assays were performed using 35S labeled in vitro translated CBP protein (100,000 
cpm) and GST-hMI-ERlB fusion protein (18 picomoles). 35S labeled in vitro translated 
CBP protein (100,000 cpm) and GST (18 picomoles) alone were tested and used as a 
control to ensure the interaction seen was not a result of CBP interacting with GST. 
Figure 3.1 is a representative autoradiograph obtained from one of the two independent 
experiments performed. As shown in Figure 3.1, the 35S labeled in vitro translated CBP 
protein interacted with GST-hMI-ER1B but not with GST alone. These results 
demonstrate that hMI-ERlB interacts with CBP in vitro. 
3.2: The amino acids of hMI-ER1B required for interaction with CBP are located in 
the region 1-179, a region rich in acidic amino acid residues 
Given that hMI-ER1B interacts with CBP in vitro, it was important to determine 
the region ofhMI-ER1B responsible for the interaction. The complete amino acid 
sequence ofhMI-ER1B shows the presence of an acidic activation domain, an ELM2 
domain and a SANT domain (Figure 3.2A). In order to investigate which domain is 
rettuired for the interaction, the following GST-hMI-ER1 deletion constructs were used in 
GST pull down assays: the acidic activation domain (aa 1-179), the ELM2 domain (aa 
164-283), the acidic activation and ELM2 domain (aa 1-283), and the SANT domain and 
B-C terminus (aa 287-512) (Figure 3.2A). 
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Figure 3.1: hMI-ERlB interacts with CBP in vitro 
GST -pull down assays were performed by incubating 35S labeled in vitro translated CBP 
protein (100,000 cpm) with either 18 picomoles ofGST alone (lane 2) or with 18 
picomoles ofGST-hMI-ER113 (GST 13; lane 3). The Input TNT lane represents 5% ofthe 
input of 35S labeled CBP protein used in each pull down assay (lane 1) and shows the 
proper position of CBP (265kDa). Proteins were resolved by SDS- PAGE and visualized 
by autoradiography. Results were obtained from two independent experiments and shown 
is a representative autoradiograph. The positions of CBP and a molecular weight marker 
are indicated. 
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Figure 3.2: The amino acids of hMI-ER16 required for interaction with CBP are 
located in the region 1-179, a region rich in acidic amino acid residues. 
(A)The schematic illustrates the deletion mutants ofhMI-ER1 fused to GST and used in 
the GST pull down assays shown in (B). A scaled representation ofhMI-ER1 and its 
domains are shown. The amino acid numbers encoding each construct is shown on the 
left, and a key for the various hMI-ER1 domains is located below the diagram. 
(B) GST pull down assays were performed by incubating in vitro translated 35S labeled 
CBP protein (100,000 cpm) with approximately 18 picomoles of one ofthe following 
hMI-ER1 deletion constructs fused to GST; 1-283 (lane 1), 1-179 (lane 2), 164-283 (lane 
3), 287-512 (lane 4), and GST alone (lane 5). The Input TNT lane represents 5% of the 
input of 35S labeled CBP protein used in each pull down assay (lane 6). Proteins were 
resolved by autoradiography. Shown is a representative autoradiograph with the position 
of CBP indicated by the arrowhead. 
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GST pull down assays were performed using 35S labeled in vitro translated CBP protein 
(100,000 cpm) and 18 picomoles of each ofthe GST-hMI-ER1B deletion constructs. As a 
control, the ability of 35S labeled in vitro translated CBP protein to interact with GST 
alone was tested. Figure 3.2B is a representative autoradiograph from two independent 
experiments and shows a strong interaction between CBP and the hMI-ERlB deletion 
construct containing the acidic activation domain and ELM2 domain (aa 1-283). No 
interaction was observed between CBP and the deletion construct harboring the SANT 
domain and B-C terminus (aa 287-512) or with the deletion construct harboring solely the 
ELM2 domain (164-283). Further analysis revealed that the hMI-ER1B deletion construct 
that is made up of amino acids 1-179 is responsible for the interaction with CBP in vitro. 
Overall, the results indicate that the region ofhMI-ER1B rich in acidic amino acids is 
responsible for the interaction with CBP. 
3.3: hMI-ERlB interacts with CBP, in HEK 293 cells, and inhibits histone 
acetylation 
In addition to testing the ability ofhMI-ER1B to physically associate with CBP in 
vitro, it was important to test whether a similar interaction occurs in vivo. This was done 
using a flag-tagged CBP (CBP) and myc-tagged hMI-ERlB (B). Transformed human 
embryonic kidney cell lines (HEK 293) were transiently cotransfected with myc + CBP,j3 
+flag, or j3 + CBP. Expression ofj3 was verified for each experiment by WB analysis, of 
whole cell extracts, using an anti-myc antibody. We attempted to examine the expression 
of CBP, using an anti-flag antibody, however the signal on the WB was weak (data not 
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shown). CBP has a molecular weight of265 kDa and is therefore a very large protein. It 
is known that high-molecular weight proteins have a low transfer efficiency, which 
results in low levels of detection on Western blots (as reviewed in Kurien and Scofield, 
2003). 
To examine the interaction between CBP and hMI-ER113, cell extracts were 
subjected to IP with anti-flag antibody, followed by Western blotting with anti-myc. As 
shown in Figure 3 .3A, no interaction occurred in the controls: cells transfected with 13 and 
flag and cells transfected with CBP and myc. However, the results revealed that 13 
coimmunoprecipitated with CBP in HEK 293 cells, suggesting that hMI-ER113 interacts 
with CBP in vivo. 
Since hMI-ER113 interacts with CBP, a histone acetyltransferase, it was important 
to determine whether hMI-ER113 had an effect on CBP activity. To determine the effects 
ofhMI-ER113 on histone acetylation by CBP, HEK 293 cells were transiently 
cotransfected with either CBP + j3 or CBP alone. Non-transfected, CBP + myc andft + 
.flag-transfected cells were used as controls. Cell extracts were subjected to IP with either 
an anti-myc or anti-flag antibody. HAT assays were then performed using HAT assay 
buffer containing Trichostatin A (TSA). TSA was included because it was shown that 
hMI-ERl interacts with histone deacetylase 1 (HDAC 1) and therefore I wanted to inhibit 
any HDAC activity associated with hMI-ERl since HDAC activity might interfere with 
our ability to detect HAT activity. 
As shown in Figure 3.3B, the control samples from the non-transfected, myc + 
CBP, and flag+ .f3-transfected cells contained very little HAT activity. The results also 
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Figure 3.3: hMI-ER1J3 interacts with CBP in vivo and inhibits histone acetylation. 
HEK 293 cells were transiently cotransfected with either myc + CBP,jlag + jJ, or CBP + 
f3 plasmids. 0.75!-lg of each plasmid was used in the cotransfections. Additional controls 
consisted ofmock-transfected 293 cells, as well as cells transfected with CBP alone, for 
use in the HAT assay. Cells were grown in DMEM rich medium (see Material and 
Methods) for 48 hours. (A) Celllysates were prepared and added directly to sample 
buffer (lanes 1 and 5) or subjected to IP with anti-flag antibody (1:750; lanes 2-4). WB 
analysis was performed using anti-myc antibody (1:100). Results were obtained from 
three independent experiments and shown is a representative WB, with the position of 
hMI-ER113 indicated by the arrowhead. (B) Additional celllysates were subjected to IP 
with anti-flag antibody (1 :750) or with anti-myc (1: 100) and assayed for HAT activity. 
The histogram shows the average values and standard deviations obtained from the three 
experiments conducted. 
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revealed that the CBP sample, in the absence of 13, contained significant HAT activity. 
However, the activity was reduced to control levels in the presence of 13. Taken together, 
the results show that hMI-ER113 interacts with CBP in vivo and suggests that this 
interaction inhibits CBP acetylase activity. 
3.4: The CBP Br-Q region (aa 1092-2441) that harbors the HAT domain is 
responsible for the interaction with hMI-ER1B in vitro. 
To determine which region of the CBP protein was responsible for the interaction 
with hMI-ER113, flag tagged deletion mutants were constructed. The schematic 
illustration of the CBP constructs, as shown in Figure 3.4A, illustrates that CBP Br-Q 
deletion construct (aa 1092-2441) is made up of the bromodomain, the HAT domain, two 
cysteine-histidine rich domains and a Q rich domain. The CBP Rid-Br construct (aa 1-
1095), however, is made up of the receptor interacting domain, a cysteine-histidine rich 
domain, and the kinase induced interacting domain. 
GST pull down assays were performed with 35S labeled in vitro translated Rid-Br 
and Br-Q protein and GST-13 fusion proteins. As controls, the ability of the deletion 
constructs to interact with GST alone was also tested. Figure 3 .4B shows the results of a 
representative GST pull down assay. As shown, the 35S labeled in vitro translated Br-Q 
protein did interact with GST -13 and not with GST alone. However, the 35S labeled in 
vitro translated Rid-Br did not interact with GST-13. The results reveal that hMI-ER1J3 
interacts with Br-Q in vitro. 
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Figure 3.4: The CBP Br-Q region (aa 1092-2441), that harbors the HAT domain, is 
responsible for the interaction with hMI-ER1B in vitro. 
(A) The schematic illustrates the deletion mutants of CBP fused to a flag tag and used in 
GST pull down assays. A scaled diagram representing CBP and its deletion mutants 
together with the number of amino acids encoding each construct is shown. 'RID': 
receptor interacting domain; 'KIX': kinase induced interacting domain; 'C/H-1,-2,-2': 
cysteine-histidine rich domains; 'Bromodomain': acetyl-lysine domain; 'HAT': histone 
acetyltransferase domain; 'Q Rich': glutamine-rich domain. (B) GST pull down assays 
were performed by incubating in vitro translated 35S labeled Rid-Brand Br-Q protein 
(100,000 cpm) with GST alone (12.3 picomoles)(lanes 2 & 4) or with GST-B (B; 12.3 
picomoles; lanes 1 & 3). The Br-Q TNT and Rid-Br TNT (lanes 5 & 6) represent 5% and 
10% of the input of 35S labeled protein used in each pull down assay respectively. 
Proteins were resolved by autoradiography. Shown is a representative autoradiograph 
with the position ofRid-Br and Br-Q indicated. 
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3.5: hMI-ER16 interacts with CBP Br-Q in vivo and inhibits histone acetylation 
In addition to testing the ability ofhMI-ERlB to physically associate with CBP 
Br-Q in vitro, it was important to test whether the interaction could also be seen in vivo. 
In vivo analysis involved the transient cotransfections with Br-Q + J3. Non-transfected, 
CBP + myc, CBP + j3, and flag+ fi-transfected HEK 293 cells were used as controls. 
Expression of B was verified by performing IP and Western blotting with an anti-myc 
antibody. Cell extracts were also subjected to IP with anti-flag antibody, followed by 
Western blotting with anti-myc. As shown in Fig. 3.5A, no interaction was found 
between B and flag. Similarly, an interaction did not occur between CBP and myc. The 
results also revealed that B interacted with Br-Q in vivo, similar to the interaction found 
between B and CBP. 
Since hMI-ERlB interacts with Br-Q, which harbors the HAT domain, it was 
important to determine ifhMI-ERlB could inhibit its ability to acetylate histones. For this 
purpose, in vitro HAT assays were performed to measure the HAT activity ofBr-Q in the 
presence and absence of B. HEK 293 cells were transfected with Br-Q,J3 + Br-Q, Br-Q + 
myc or j3 +flag plasmids. Mock transfected cells were used as an additional control. Cell 
extracts were subjected to IP with either an anti-myc or anti-flag antibody and assayed for 
HAT activity. As shown in Figure 3.5B, the control samples from the non-transfected, 
and myc + Br-Q- transfected cells contained very little HAT activity. The results also 
revealed that Br-Q, in the absence of 13, contains significant HAT activity. However, the 
activity was reduced to control levels in the presence of 13. Taken together, the overall 
results show that hMI-ERlB interacts with Br-Q in vivo and inhibits histone acetylation. 
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Figure 3.5: hMI-ERlB interacts with CBP Br-Q in vivo and inhibits histone 
acetylation. HEK 293 cells were transiently cotransfected with myc + CBP, B + CBP, 
flag+ B, or Br-Q + j3 plasmids. (A) Celllysates were prepared 48 hours after transfection 
and subjected to IP with anti-flag antibody (flag; 1 :750; lanes 1, 3-6) or with anti-myc 
antibody (myc; 1:100; lane 2). WB analysis was performed using anti-myc antibody 
(1: 1000). Results were obtained from three independent experiments and shown is a 
representative WB, with the position ofhMI-ER1B indicated by the arrowhead. (B) 
Additional celllysates were subjected to IP with anti-flag antibody (1 :750) or with anti-
myc antibody (1: 1 00) and further examined for HAT activity. The histogram shows the 
average values and standard deviations obtained from the experiments conducted. 
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3.6: Inhibition of histone acetylation in vitro by hMI-ER1.6 is not the result of 
competition for histone binding. 
There are many different ways in which hMI-ER1B could be affecting histone 
acetylation. For instance, hMI-ER1B could bind to histones and prevent them from being 
acetyltransferase substrates. As well, it is also possible that the res"\llts obtained are a 
result ofhMI-ERlB selectively binding to inactive CBP. Finally, it is also possible that 
hMI-ER1B is inhibiting histone acetylation by affecting the conformation of CBP. Such a 
conformational change could alter the enzymatic activity of CBP and prevent histone 
acetylation. 
Preliminary studies in our laboratory have demonstrated that hMI-ER1 binds to 
unacetylated histone H4 in vitro (Ding et al., unpublished data), initially suggesting a 
possible mechanism of HAT inhibition. Such a mechanism of HAT inhibition is not 
uncommon. For instance, it has been recently shown that a cellular complex termed 
INHAT (inhibitor of acetyltransferases) binds to histones and inhibits p300, CBP and 
PCAF mediated histone acetylation (Seo et al., 2001 ), a mechanism known as histone 
masking. In general "histone masking" refers to the ability of a protein/s to bind to 
histones and mask them from being acetyltransferase substrates. Therefore, to further 
in~estigate the ability ofhMI-ER1B to inhibit histone acetylation, it was important to 
determine if hMI-ER 1 B competes for histone binding. 
To test whether hMI-ER113 inhibits histone acetylation by competing for histone 
binding, HEK 293 cells were transiently cotransfected with the following plasmids: myc 
+ Br-Q, j3 + Br-Q, orj3 +flag. Cell extracts were subjected to IP with anti-flag or with 
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anti-myc antibody and HAT assays were performed. The ability ofBr-Q to acetylate 
histones, in the presence and absence of B, was used in each experiment as positive and 
negative controls respectively. Additional samples immunoprecipitated for Br-Q were 
incubated with HAT master mix that had been preincubated with B for 45 minutes at 
37°C, and HAT assays were then performed. HAT master mix preincubated with myc or 
preincubated HAT master mix alone was added to immunoprecipitated Br-Q and used as 
a control. 
IfhMI-ERlB competes for histone binding, few histones would remain in the 
supernatant and very little HAT activity should be recovered when incubated with Br-Q. 
However, ifHMI-ERlB does not compete for histone binding, the histones would remain 
in the supernatant and similar HAT activity should be detected as with the control (Br-Q 
incubated with HAT master mix preincubated with mix or preincubated alone). 
Figure 3.6A shows that as expected, myc does not contain significant amounts of 
HAT activity and that the ability ofBr-Q to acetylate histones was dramatically reduced 
in the presence of B. In addition, Figure 3.6A shows that the Br-Q sample incubated with 
HAT master mix preincubated with immunoprecipitated B for 45 minutes at 37°C 
contains similar HAT activity to the controls (Br-Q incubated with HAT master mix 
preincubated with myc or preincubated alone). These results suggest that inhibition of 
histone acetylation by hMI-ERlB, in vitro, is not the result of competition for histone 
binding. 
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Figure 3.6: Inhibition of histone acetylation in vitro by hMI-ER16 is not the result of 
competition for histone binding. HEK 293 Cells were transiently cotransfected with a 
total of 1.5).1.g of myc + Br-Q,j3 + Br-Q, or j3 +flag plasmids. Cell extracts were prepared 
48 hours after transfection. (A) Celllysates were further subjected to IP with anti-flag 
antibody (IP-flag; 1:750; lanes 3, 4, 5) or with anti-myc antibody (IP-myc; 1:100; lanes 1 
& 2). HAT assays were performed as previously described and the samples were assayed 
for HAT activity (samples 1&2). Additional samples were incubated with HAT master 
mix preincubated with immunoprecipitated 13 (MMPre13; lane 3), preincubated alone 
(MMPre; lane 4) or preincubated with immunoprecipitated myc (MMPremyc; lane 5). 
The histogram shows the average values and standard deviations from three independent 
experiments. Cells were also cotransfected with Br-Q + myc and the lysates subjected to 
IP with anti-flag. HAT assays were then performed on the samples and the overall results 
were normalized by the Br-Q activity to account for variance between experiments. (B) 
Additional celllysates were added directly to sample buffer (lanes 1-5). WB analysis was 
performed using anti-flag antibody (anti-flag; 1 :2000; lanes 1&2) or anti-myc antibody 
(anti-myc; 1:1 000; lanes 3-5). Results were obtained from three independent experiments 
and shown is a representative WB, with the position of 13 and Br-Q indicated by the 
arrowheads. 
For these experiments, the expression ofj3 and Br-Q in transfected HEK 293 cells 
was verified by WB using an anti-flag or anti-myc antibody. As shown in Figure 3.6B, 
both proteins were significantly expressed in all samples tested for HAT activity. 
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3.7: hMI-ERlJl does not selectively bind to inactive CBP 
As mentioned, it is also possible that the results obtained are a result ofhMI-
ER113 selectively binding to inactive CBP. The function of CBP, like most proteins, can 
be regulated by activating or inactivating its enzymatic activity. For instance, 
phosphorylation of CBP by cyclin E/Cdk2 increases HAT activity in vitro (Ait-Si-Ali et 
al., 1998). As well, the protein E1A has been recently shown to inactivate CBP by 
binding to the C/H3 region and repressing its HAT activity (Chakravarti et al., 1999). 
HEK 293 cells were transiently cotransfected with myc + Br-Q, or j3 + Br-Q 
plasmids. Cell extracts were immunoprecipitated with an anti-myc or anti-flag antibody 
and assayed for HAT activity. To determine whether or not hMI-ER113 selectively binds 
to inactive CBP the supernatant was also recovered from both samples, 
immunoprecipitated with an anti-flag antibody, and assayed for HAT activity. IfhMI-
ER113 only binds to inactive Br-Q, all of the active Br-Q would remain in the supernatant. 
Therefore, one would expect to recover almost all of the same HAT activity as with Br-Q 
alone. However, ifhMI-ER113 selectively binds to active Br-Q, all of the inactive Br-Q 
would remain in the supernatant and one would expect to recover very little HAT 
activity. Finally, ifhMI-ER113 binds to both inactive and active Br-Q one would expect to 
r~over less HAT activity as with Br-Q alone. 
As shown in Figure 3.7A, myc does not contain any HAT activity similar to the 
results seen with Br-Q in the presence of 13. The results also show that the supernatant 
from the Br-Q sample preincubated with 13 contained approximately half of the HAT 
activity as compared to the control (supernatant IP for Br-Q preincubated with myc), and 
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contained approximately 50 times more HAT activity than Br-Q in the presence of B. The 
results reveal that hMI-ERlB does not selectively bind to inactive CBP in vitro. 
For these experiments, the expression of J3 and Br-Q in transfected HEK 293 cells 
was verified by WB using an anti-flag or anti-myc antibody. As shown in Figure 3.7B, 
both proteins were expressed in all samples tested for HAT activity. 
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Figure 3.7: hMI-ERlB does not selectively bind to inactive CBP. HEK 293 Cells 
were transiently cotransfected with a total of 1.5 !J.g of either j3 + Br-Q, or myc + Br-Q 
plasmids, with cell extracts prepared 48 hours after transfection. (A) Celllysates were 
subjected to IP with anti-myc antibody ( anti-myc; 1:1 00) and the immunoprecipitated 
pellet (IP-Pellet) was assayed for HAT activity (lanes 2&4). The supernatant from each 
samples was immunoprecipitated with anti-flag antibody (IP-Sup) and then assayed for 
HAT activity (lanes 1&3). The histogram shows the average values and standard 
deviations from three independent experiments. (B) Additional celllysates were added 
directly to sample buffer (lanes 1-4). WB analysis was performed using anti-flag 
antibody (anti-flag; 1:2000; lanes 1&2) or anti-myc antibody (anti-myc; 1:1000; lanes 
3&4). Results were obtained from three independent experiments and shown is a 
representative WB, with the position of Band Br-Q indicated. 
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Chapter 4: Discussion 
The deregulation of gene expression plays a very important role in the 
development of cancer. The altered patterns of gene expression are often the result of the 
inappropriate expression of a specific transcriptional activator or repressor (Kirmizis and 
Farham, 2004). For instance, the BRCA1 protein is a transcriptional regulator that is 
found to be mutated in approximately 8% ofbreast cancer cells. A mutation in BRCA1 
increases the transcription of target genes by ERa, estrogen receptor a, thereby promoting 
proliferation of abnormal cells (Zheng et al., 2001). Proto-oncogenes, or genes that have 
cancer causing potential, also play a very important role in breast cancer. For example, 
Her2, human epidermal growth factor receptor-type 2, is one proto-oncogene found to be 
overexpressed in 10-40% human breast cancer. An excess ofHer2 protein signals for 
cells to divide, multiply and grow at a faster rate than normal cells, thus contributing to 
the occurrence and progression of cancer (Kurebayashi., 2001). 
Previous studies have revealed that hmi-er 1 expression was upregulated in breast 
carcinoma cell lines and breast tissue, suggesting that hmi-er 1 is associated with the 
neoplastic state of human breast carcinoma (Paterno et al., 1998). Recent work has also 
shown that hMI-ER1 can function as a transcriptional repressor by recruiting histone 
.,. 
deacetylase, HDAC1, to its ELM2 domain. The results suggest a connection exists 
between hmi-erl upregulation in breast cancer and its role in transcriptional regulation. 
The role ofhMI-ER1 in transcriptional regulation is therefore very important, and further 
investigation is needed. 
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As mentioned, hMI-ERl consists of many evolutionary conserved domains, such 
as the acidic activation domain, the ELM2 domain and the SANT domain. Although a list 
of interacting proteins has not been fully established, the presence of these domains 
suggests that there are potentially many possible interacting proteins. For example, the 
SANT domain within Ada2 has been shown to interact with the histone acetyltransferase, 
GenS. It was also shown that the interaction is needed for effective histone acetylation by 
GenS (Sterner et al., 2002). Because hMI-ER1 contains a SANT domain, similar to that 
of Ada2, it was initially hypothesized that hMI-ER1 would also interact with a histone 
acetyl transferase, particularly CBP. An interaction between the two proteins is of interest 
because CBP plays a very important role in transcriptional regulation. The regulation of 
gene transcription is very complex in that it involves DNA-binding transcription factors, 
chromatin remodeling enzymes such as CBP, p300, PCAF, as well as other cofactors 
such as SRC and p/CIP (Perissi et al., 1999a). The histone acetyl transferase function of 
CBP, as well as other histone acetylases, has proven critical for transcription function 
(Chrivia et al., 1993), through its ability to modify chromatin structure, suggesting that 
gene regulation is tightly regulated. In addition, CBP can play an indirect role in 
transcriptional regulation by acetylating DNA binding transcription factors, such as p53 
ana GATA-1. Upon acetylation, these proteins have been shown to have increased DNA 
binding potential (Gu and Roeder, 1997; Boyes et al., 1998). 
When compared to other histone acetyltransferases, CBP plays a critical role in a 
wide variety of cellular processes, including cell cycle control, differentiation and 
apoptosis. Mutations in CBP are associated with certain cancers and other human disease 
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processes. As a global coactivator in higher eukaryotes, CBP is one of the most potent 
and versatile of the histone acetyltransferases (Sterner et al., 2000). 
As expected, an interaction between hMI-ER1B and CBP was originally 
discovered in vitro, by performing GST pull down assays (Figure 3.1). However, unlike 
originally hypothesized, the SANT domain ofhMI-ER1B was not responsible for the 
interaction between the two proteins in vitro (Figure 3.7) Instead, a series ofGST pull 
down assays demonstrated that it was the region found at theN-terminus ofhMI-ER1, 
encompassing amino acids 1-179 containing the four stretches of highly acidic regions 
that is responsible. As mentioned, it was known that acidic amino acids play a very 
important role in transcriptional activation and the deletion construct harboring the first 3 
acidic amino acid stretches (aa 1-98) ofXMI-ER1 stimulated transcription 80 fold 
(Paterno et al., 1997). The finding that it is the region encompassing amino acids 1-179 
that was responsible for the interaction, suggests that it may also be the region 
responsible for HAT inhibition as well. The involvement of acidic residues in inhibition 
of HAT activity is not uncommon. It was recently shown that the major HAT inhibitory 
domain ofpp32 resides within a region of the acidic C-terminal residues (Seo et al., 
2002). In addition, similar results were found for the Set/Taf-IB and TAF-Ia proteins (Seo 
et til., 2001 ). It would be of interest to develop further constructs containing various 
deletions of the four stretches of acidic amino acids found at theN-terminus ofhMI-ERl 
for use in future GST pull down assays. The results would allow for the identification of 
the amino acids responsible for the interaction. Further HAT assays could be conducted 
using the deletion constructs to determine if the region for the interaction is also the 
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HAT inhibitory function. Overall, the results would map the HAT interacting and 
inhibiting domain(s) ofhMI-ERl. 
To further confirm that an interaction occurs between hMI-ERlf3 and CBP, in 
vivo assays were conducted. HEK 293 cells were co-transfected with various 
combinations of hMI-ERI./3 and CBP and cell extracts immunoprecipiated with an 
antibody for CBP. Western blotting was performed with an antibody for hMI-ERlf3 and 
the results showed an interaction occurred between hMI-ERlf3 and CBP (Figure 3.2). To 
further confirm that an interaction is not an artifact of overexpression, endogenous 
experiments were performed. However, problems were encountered trying to detect the 
CBP or hMI-ERl protein (data not shown). It is well known that very large proteins, such 
as CBP, do not transfer very well during immunoblotting, which results in low levels of 
detection (as reviewed in Kurien and Scofield, 2003). Attempts were made to increase 
transfer efficiency by transferring for a longer period of time and lowering the percentage 
of gels used. However, the CBP protein could not be clearly detected. It is also possible 
that both proteins do interact within a cell however a better antibody or increased transfer 
efficiency is required for the detection. Therefore, future studies would include further 
testing for an endogenous interaction between CBP and hMI-ERl . 
., As mentioned, CBP mutations and inactivity is often associated with disease and 
hMI-ERJ is upregulated in breast carcinoma. It was therefore important to further 
investigate the role ofhMI-ERl with respect to transcriptional regulation. In vitro HAT 
assays were performed on CBP and hMI-ERlf3 protein co-expressed in HEK 293 cells. It 
was found that hMI-ERl inhibits the ability ofCBP to acetylate histones (Figure 3.3), 
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and therefore may function to repress transcription through such a mechanism. The 
concept that a protein can bind to CBP and repress transcription is not a novel idea. For 
instance, the Kaposi's sarcoma-associated herpesvirus K8 protein, p34SEI-1, the 
adenovirus ElA, RSK2, and PU.1 are all proteins that have been recently shown to 
repress the HAT activity ofCBP (Chakravarti et al., 1999; Merienne et al., 2001; Hwang 
et al., 2001; Hong et al., 2002; Hirose et al., 2003). 
How CBP is regulated within a cell is still not fully understood. However, many 
studies have been conducted to determine if a protein regulates the HAT activity of CBP 
by either altering histone/ substrate recognition or the enzymatic activity of CBP. For 
instance, it has recently been shown that a multiprotein cellular complex, INHAT 
(inhibitor of acetyltransferases), associates with histones in vivo and blocks them from 
serving as acetylase substrates, suggesting a critical role for histone binding in HAT 
inhibition (Seo et al., 2002). Therefore, the next goal was to determine ifhMI-ERl 
competes for histone binding blocking them from serving as acetylase substrates. Further 
HAT Assays were conducted and the results revealed that the inhibition ofhistone 
acetylation by hMI-ER1B in vitro is not the result of competition for histone binding 
(Figure 3.5) . 
.,. It is also possible that hMI-ERlB selectively binds to inactive CBP. HAT assays 
were carried out to determine ifhMI-ER1B interacts with inactive CBP, active CBP, or 
both. The results obtained suggest that hMI-ER113 binds to both inactive and active CBP, 
and with binding, hMI-ER1 functions to repress the HAT activity of previously active 
CBP (Figure 3.6). 
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Although the exact mechanisms of histone acetyltransferase inhibition have not 
yet been fully determined, many studies suggest that an interaction with CBP could 
induce conformational changes. Such a conformational change could alter the enzymatic 
activity ofCBP. For instance, the HAT domain is adjacent to the C/H3 region ofCBP, 
and it is often this region that corresponds to a variety of protein binding sites. The RSK-
2, E1A, and KSHV proteins all inhibit acetyltransferase activity of CBP by binding to the 
C/H3 domain (Perissi et al., 1999b;Merienne et al., 2001;Hwang et al., 2001). Structural 
studies, such as structural proteomics, could be conducted in the future to determine 
whether or not the conformation of CBP changes in the presence and absence of hMI-
ER1. Structural proteomics is a recent development to help determine three dimensional 
protein structures and has a major application in the area of oncology (Jung and Lew, 
2004). 
It has also been shown that the adenoviral E1A oncoprotein represses 
transcription by binding to the C/H3 region of CBP thereby displacing the PCAF and 
p/CIP proteins form the complex (Chakravarti et al., 1999). CBP is also found in an 
enzymatic complex with a variety of other histone acetylases, therefore the results 
suggest another possible mechanism of HAT inhibition upon protein binding . 
., In an attempt to further map the CBP domain/s involved in the physical 
interaction with hMI-ER1, CBP deletion mutants were made and used in pull down 
assays. The results reveal that the domain responsible for the interaction in vitro and in 
vivo is found between amino acids 1092-2441 which harbors the HAT, bromodomain, 
CIH2, C/H3, and Q-rich domains (Figures 3.4 & 3.5). In addition, no interaction was 
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found between the region encompassing amino acids 1-1095, which harbors the receptor 
interacting domain, the C/H1, and kinase induced interacting domain (Figure 3.4). In the 
future it would be of interest to further map the domain responsible by constructing CBP 
deletion constructs harboring each individual domain and performing GST pull down 
assays and co-transfections. 
With the results obtained it is possible that hMI-ERl could play a role in 
repressing transcription by interacting with CBP and inhibiting acetylation of histones. It 
has been demonstrated that hMI-ERl binds to HDACl and functions to repress 
transcription. However the regulation of gene transcription, although extensively studied, 
has not been fully established. It is known that the acetylation state ofhistones is 
reversibly regulated by HAT and HDAC, and an imbalance between the two leads to 
abnormal behavior of the cell in morphology, cell cycle, differentiation and 
carcinogenesis (as reviewed in Kim et al., 2003). Numerous studies also suggest that 
HDAC and HAT activity may not act independently and that their activity may be linked 
to one another (Perez-Martin and Johnson, 1998;Wittschieben et al., 1999;Vogelauer et 
al., 2000). For example, the proteins YYl and Spl interact with both HAT and HDAC, 
thereby acquiring an activator or repressor function depending on the promoter context 
anti other factors (Cress and Seto, 2000). In general, the results suggest that hMI-ERl 
may function to repress transcription by regulating the activity of both HAT and HDAC. 
A regulation ofboth enzymes might ensure continuous transcriptional repression, 
preventing a switch to a transcriptionally active state. 
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Future studies are needed to more precisely determine the effect that hMI-ERl 
has on HAT -mediated gene transcription. It is well documented that CBP plays a role in 
the development of a variety of diseases and that hmi-er 1 is upregulated in breast 
carcinoma cell lines and tissues, therefore a further understanding of the interaction 
between both proteins is needed. The results obtained in the present study indicate that 
hMI-ERl plays a role in the functioning of CBP and therefore could have a huge impact 
on the development of breast cancer and other diseases where CBP is important in 
chromatin remodeling and gene expression. 
One future goal is to further identify the region of CBP responsible for the 
interaction with hMI-ER 1. Identifying the exact region might suggest a mechanism for 
HAT inhibition. To do this, GST pull down assays could be performed, using various 
deletions of the CBP Br-Q construct, to determine the interacting region in vitro. In 
addition, the deletion constructs could be used in a series of co-transfection assays with 
hmi-er 1 to determine the region responsible in vivo. 
Although an interaction between CBP and hMI-ERl was found in HEK 293 cells, 
it is possible that the results obtained are an artifact of the over-expression of both 
proteins. Therefore, further endogenous testing is required to support the findings thus 
far. In addition, experiments could be conducted to co-localize CBP and hMI-ERl in the 
cell. To do this, immunocytochemistry and laser scanning confocal microscopy would be 
useful in an attempt to support the evidence for endogenous interaction. It would be 
possible that the interaction seen, as well as the effects ofhMI-ERl on CBP function, is 
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HEK 293 cell specific. In the future, it would be of interest to perform co-transfection, 
endogenous, and HAT assays on a variety of cell lines. 
The demonstration that hMI-ERl repressed HAT activity suggests that hMI-ERl 
may play a role in HAT -mediated transcription. It has been shown that a Gal4-DNA 
binding domain fusion of CBP activates transcription in a HAT dependent manner when 
transfected with a TK-Luc reporter gene sensitive to CBP (Martinez-Balbas eta!., 
1998;Seo eta!., 2001). Co-transfection of the Gal4-CBP and various hmi-erl constructs 
could be performed and the expression of Gal4 responsive reporter gene could be 
analyzed. The results would suggest whether or not hMI-ERl has a regulatory role in 
HAT -mediated transcription. 
It would also be of interest to determine ifhMI-ERl interacts with other histone 
acetyltransferases in vivo. For instance, Chakravarti et al. have recently shown that the 
adenovirus ElA interacts with CBP, p300, and PCAF and represses their HAT activity. It 
has been shown that ElA represses transcription by binding to the C/H3 region of both 
CBP and p300 thereby displacing PCAF and p/CIP proteins from the complex. In 
addition, the binding ofElA to theN terminus ofPCAF may further repress 
transcription, since p300 and CBP also binds to theN terminus ofPCAF (Chakravarti et 
al~ 1999). Therefore, similar to the ElA protein, hMI-ERl might also interact with such 
HATs as PCAF, p300, and GenS and possibly inhibit their HAT activity. 
It has also been demonstrated that hMI-ERl inhibits the ability ofCBP to 
acetylate the histone H4 peptide in vitro. Additional HAT assays could be employed 
using other individual histone subunits, such as histone H2A, H2B, and H3. It is possible 
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that hMI-ERl may not have the same effect on acetylation of the other histones 
mentioned. Lastly, it would be of interest to purify chromatin (DNA wrapped around 
histones H2A, H2B, H3 and H4) from cells, to act as a natural template in HAT assays in 
the presence and absence ofhMI-ERl. From this, the histones can be separated on a gel 
and the acetylation state of each specific histone determined. With the histones in a more 
natural state, the effects ofhMI-ERl on each specific histone can be precisely 
determined. 
In conclusion, the purpose of this study was to determine ifhMI-ERlB could 
interact with CBP. If an interaction occurred, we wanted to determine the region of both 
CBP and hMI-ERlB responsible and the effects ofhMI-ERl on CBP function. 
The results clearly showed that hMI-ERl does interact with CBP in vitro and in 
vivo, and it is a region found within the acidic activation domain ofhMI-ERl that is 
responsible. As well, further analysis revealed that hMI-ERl functions to repress the 
HAT activity ofCBP. Overall, the results suggest that hMI-ERl may play a role in HAT-
mediated transcription. 
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